A device that substitutes for a heart valve. It may be composed of biological material (BIOPROSTHESIS) and/or synthetic material.
Surgical insertion of cylindric hydraulic devices for the treatment of organic ERECTILE DYSFUNCTION.
Rigid, semi-rigid, or inflatable cylindric hydraulic devices, with either combined or separate reservoir and pumping systems, implanted for the surgical treatment of organic ERECTILE DYSFUNCTION.
Surgical insertion of synthetic material to repair injured or diseased heart valves.
The valve between the left ventricle and the ascending aorta which prevents backflow into the left ventricle.
Flaps of tissue that prevent regurgitation of BLOOD from the HEART VENTRICLES to the HEART ATRIA or from the PULMONARY ARTERIES or AORTA to the ventricles.
Surgical insertion of an appliance for the replacement of areas of the mandible.
Prosthesis, usually heart valve, composed of biological material and whose durability depends upon the stability of the material after pretreatment, rather than regeneration by host cell ingrowth. Durability is achieved 1, mechanically by the interposition of a cloth, usually polytetrafluoroethylene, between the host and the graft, and 2, chemically by stabilization of the tissue by intermolecular linking, usually with glutaraldehyde, after removal of antigenic components, or the use of reconstituted and restructured biopolymers.
Surgical insertion of an appliance for the replacement of areas of the maxilla, mandible, and face. When only portions of the mandible are replaced, it is referred to as MANDIBULAR PROSTHESIS IMPLANTATION.
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).
The valve between the left atrium and left ventricle of the heart.
The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction.
The plan and delineation of prostheses in general or a specific prosthesis.
The external reproductive organ of males. It is composed of a mass of erectile tissue enclosed in three cylindrical fibrous compartments. Two of the three compartments, the corpus cavernosa, are placed side-by-side along the upper part of the organ. The third compartment below, the corpus spongiosum, houses the urethra.
Agents that prevent clotting.
A pathological constriction that can occur above (supravalvular stenosis), below (subvalvular stenosis), or at the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA.
Malfunction of implantation shunts, valves, etc., and prosthesis loosening, migration, and breaking.
Pathological condition characterized by the backflow of blood from the ASCENDING AORTA back into the LEFT VENTRICLE, leading to regurgitation. It is caused by diseases of the AORTIC VALVE or its surrounding tissue (aortic root).
The hollow, muscular organ that maintains the circulation of the blood.
Surgical insertion of a prosthesis.
Artificial substitutes for body parts, and materials inserted into tissue for functional, cosmetic, or therapeutic purposes. Prostheses can be functional, as in the case of artificial arms and legs, or cosmetic, as in the case of an artificial eye. Implants, all surgically inserted or grafted into the body, tend to be used therapeutically. IMPLANTS, EXPERIMENTAL is available for those used experimentally.
The valve consisting of three cusps situated between the right atrium and right ventricle of the heart.
Prostheses used to partially or totally replace a human or animal joint. (from UMDNS, 1999)
Backflow of blood from the LEFT VENTRICLE into the LEFT ATRIUM due to imperfect closure of the MITRAL VALVE. This can lead to mitral valve regurgitation.
A valve situated at the entrance to the pulmonary trunk from the right ventricle.
Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.
Replacement for a knee joint.
Replacement for a hip joint.
Graphic registration of the heart sounds picked up as vibrations and transformed by a piezoelectric crystal microphone into a varying electrical output according to the stresses imposed by the sound waves. The electrical output is amplified by a stethograph amplifier and recorded by a device incorporated into the electrocardiograph or by a multichannel recording machine.
Narrowing of the passage through the MITRAL VALVE due to FIBROSIS, and CALCINOSIS in the leaflets and chordal areas. This elevates the left atrial pressure which, in turn, raises pulmonary venous and capillary pressure leading to bouts of DYSPNEA and TACHYCARDIA during physical exertion. RHEUMATIC FEVER is its primary cause.
Procedures in which placement of CARDIAC CATHETERS is performed for therapeutic or diagnostic procedures.
A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery.
System established by the World Health Organization and the International Committee on Thrombosis and Hemostasis for monitoring and reporting blood coagulation tests. Under this system, results are standardized using the International Sensitivity Index for the particular test reagent/instrument combination used.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues using a transducer placed in the esophagus.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
The co-occurrence of pregnancy and a cardiovascular disease. The disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS.
Removal of an implanted therapeutic or prosthetic device.
A disorder characterized by sudden attacks of respiratory distress in at rest patients with HEART FAILURE and PULMONARY EDEMA. It usually occurs at night after several hours of sleep in a reclining position. Patients awaken with a feeling of suffocation, coughing, a cold sweat, and TACHYCARDIA. When there is significant WHEEZING, it is called cardiac asthma.
The number of times the HEART VENTRICLES contract per unit of time, usually per minute.
Artificial device such as an externally-worn camera attached to a stimulator on the RETINA, OPTIC NERVE, or VISUAL CORTEX, intended to restore or amplify vision.
Formation and development of a thrombus or blood clot in the blood vessel.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Prosthetic replacements for arms, legs, and parts thereof.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic.
Elements of limited time intervals, contributing to particular results or situations.
The fitting and adjusting of artificial parts of the body. (From Stedman's, 26th ed)
Measurement of intracardiac blood flow using an M-mode and/or two-dimensional (2-D) echocardiogram while simultaneously recording the spectrum of the audible Doppler signal (e.g., velocity, direction, amplitude, intensity, timing) reflected from the moving column of red blood cells.
Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening.
Medical devices which substitute for a nervous system function by electrically stimulating the nerves directly and monitoring the response to the electrical stimulation.
Abnormal protrusion or billowing of one or both of the leaflets of MITRAL VALVE into the LEFT ATRIUM during SYSTOLE. This allows the backflow of blood into left atrium leading to MITRAL VALVE INSUFFICIENCY; SYSTOLIC MURMURS; or CARDIAC ARRHYTHMIA.
An implant used to replace one or more of the ear ossicles. They are usually made of plastic, Gelfoam, ceramic, or stainless steel.
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
An artificial replacement for one or more natural teeth or part of a tooth, or associated structures, ranging from a portion of a tooth to a complete denture. The dental prosthesis is used for cosmetic or functional reasons, or both. DENTURES and specific types of dentures are also available. (From Boucher's Clinical Dental Terminology, 4th ed, p244 & Jablonski, Dictionary of Dentistry, 1992, p643)
Surgical insertion of BLOOD VESSEL PROSTHESES to repair injured or diseased blood vessels.
Flaps within the VEINS that allow the blood to flow only in one direction. They are usually in the medium size veins that carry blood to the heart against gravity.
Infections resulting from the implantation of prosthetic devices. The infections may be acquired from intraoperative contamination (early) or hematogenously acquired from other sites (late).
Backflow of blood from the RIGHT VENTRICLE into the RIGHT ATRIUM due to imperfect closure of the TRICUSPID VALVE.
Pathological conditions involving the HEART including its structural and functional abnormalities.
Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.
Device constructed of either synthetic or biological material that is used for the repair of injured or diseased blood vessels.
Generating tissue in vitro for clinical applications, such as replacing wounded tissues or impaired organs. The use of TISSUE SCAFFOLDING enables the generation of complex multi-layered tissues and tissue structures.
A prosthesis that gains its support, stability, and retention from a substructure that is implanted under the soft tissues of the basal seat of the device and is in contact with bone. (From Boucher's Clinical Dental Terminology, 4th ed)
Delay in the attachment and implantation of BLASTOCYST to the uterine ENDOMETRIUM. The blastocyst remains unattached beyond the normal duration thus delaying embryonic development.
Pathologic deposition of calcium salts in tissues.
Surgical insertion of an electronic hearing device (COCHLEAR IMPLANTS) with electrodes to the COCHLEAR NERVE in the inner ear to create sound sensation in patients with residual nerve fibers.
A device, activated electronically or by expired pulmonary air, which simulates laryngeal activity and enables a laryngectomized person to speak. Examples of the pneumatic mechanical device are the Tokyo and Van Hunen artificial larynges. Electronic devices include the Western Electric electrolarynx, Tait oral vibrator, Cooper-Rand electrolarynx and the Ticchioni pipe.
Partial or total replacement of a joint.
Implants constructed of materials designed to be absorbed by the body without producing an immune response. They are usually composed of plastics and are frequently used in orthopedics and orthodontics.
A prosthetic appliance for the replacement of areas of the maxilla, mandible, and face, missing as a result of deformity, disease, injury, or surgery. When the prosthesis replaces portions of the mandible only, it is referred to as MANDIBULAR PROSTHESIS.
A ready-made or custom-made prosthesis of glass or plastic shaped and colored to resemble the anterior portion of a normal eye and used for cosmetic reasons. It is attached to the anterior portion of an orbital implant (ORBITAL IMPLANTS) which is placed in the socket of an enucleated or eviscerated eye. (From Dorland, 28th ed)
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The transference of a heart from one human or animal to another.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.

Animal experimental implantation of an atrial septal defect occluder system. (1/2034)

OBJECTIVE: To establish the implantation technique for the atrial septal defect occluder system (ASDOS) device in an experimental animal model and to determine long term mechanical stability of the device and its in vivo properties in terms of biocompatibility and tissue reaction. MATERIALS AND METHODS: An atrial septal defect was created and the device implanted in 17 pigs (mean weight 30 kg). The implantation technique was refined and modified because of initial technical and anatomical complications during nine acute pilot studies. The technique proved to be feasible in eight subsequent survival studies. Four pigs were electively killed three months after implantation (group 1). The remaining four pigs were killed six months after implantation (group 2). RESULTS: Necropsy showed all devices were embedded in soft tissue three months after implantation. Microscopic examination of atrial septal tissue showed an acute granulomatous inflammatory reaction in group 1 and fibrosis in group 2. The intensity of the inflammatory reaction around the device was clearly milder in group 2, indicating a decline in the inflammatory response with time. Clinical and biochemical investigations indicated acceptable biocompatibility of the device. CONCLUSION: The implantation technique for the ASDOS device in a chronic pig model has been established. Biocompatibility of the device was acceptable.  (+info)

Bileaflet mechanical prostheses for aortic valve replacement in patients younger than 65 years and 65 years of age or older: major thromboembolic and hemorrhagic complications. (2/2034)

OBJECTIVE: To determine major thromboembolic and hemorrhagic complications and predictive risk factors associated with aortic valve replacement (AVR), using bileaflet mechanical prostheses (CarboMedics and St. Jude Medical). DESIGN: A case series. SETTING: Cardiac surgical services at the teaching institutions of the University of British Columbia. PATIENTS AND METHODS: Patients 2 age groups who had undergone AVR between 1989 and 1994 were studied. Group 1 comprised 384 patients younger than 65 years. Group 2 comprised 215 patients 65 years of age and older. RESULTS: The linearized rates of major thromboembolism (TE) occurring after AVR were 1.54%/patient-year for group 1 and 3.32%/patient-year for group 2; the rates for major TE occurring more than 30 days after AVR were 1.13%/patient-year for group 1 and 1.55%/patient-year for group 2. The crude rates for major TE occurring within 30 days of AVR were 1.04% for group 1 and 3.72% for group 2. The death rate from major TE in group 1 was 0.31%/patient-year and in group 2 was 0.88%/patient-year. Of the major TE events occurring within 30 days, 100% of patients in both age groups were inadequately anticoagulated at the time of the event, and for events occurring more than 30 days after AVR, 45% in group 1 and 57% in group 2 were inadequately anticoagulated (INR less than 2.0). The overall linearized rates of major hemorrhage were 1.54%/patient-year for group 1 and 2.21%/patient-year for group 2. There were no cases of prosthesis thrombosis in either group. The mean (and standard error) overall freedom from major TE for group 1 patients at 5 years was 95.6% (1.4%) and with exclusion of early events was 96.7% (1.3%); for group 2 patients the rates were 90.0% (3.2%) and 93.7% (3.0%), respectively. The mean (and SE) overall freedom from major and fatal TE and hemorrhage for group 1 patients was 90.1% (2.3%) and with exclusion of early events was 91.2% (2.3%); for group 2 patients the rates were 87.9% (3.1%) and 92.5% (2.9%), respectively. The 5-year rate for freedom from valve-related death for group 1 patients was 96.3% (2.1%) and for group 2 patients was 97.2% (1.2%). CONCLUSION: The thromboembolic and hemorrhagic complications after AVR with bileaflet mechanical prostheses occur more frequently and result in more deaths in patients 65 years of age and older than in patients years younger than 65 years.  (+info)

Minimally invasive aortic valve replacement through a transverse sternotomy: a word of caution. (3/2034)

OBJECTIVES: To compare aortic valve replacement (AVR) using a minimally invasive approach through a transverse sternotomy with the established approach of median sternotomy. DESIGN: Retrospective, case-control study. PATIENTS: Fourteen high risk patients (median age 78, Parsonnet score of 18%) who underwent AVR performed through a minimally invasive transverse sternotomy were compared with a historical group of patients matched for age, sex, and Parsonnet score who underwent AVR performed through a median sternotomy by the same surgeon. OUTCOME MEASURES: Cross clamp time, total bypass time, intensive care stay, postoperative in-hospital stay, morbidity, and mortality. RESULTS: There were two deaths in the minimally invasive group and none in the control group (NS). The cross clamp and total bypass times were longer in the minimally invasive group (67 and 92 minutes v 46 and 66 minutes, p < 0.001). There was a higher incidence of re-exploration for bleeding (14% v 0%) and paravalvar leaks (21% v 0%) in the minimally invasive group but these differences were not significant. The minimally invasive group had a longer postoperative in-hospital stay (p = 0.025). The incidence of mortality or major morbidity was 43% (six of 14) in the minimally invasive group and 7% (one of 14) in the matched pairs (p = 0.013). CONCLUSIONS: AVR can be performed through a transverse sternotomy but the operation takes longer and there is an unacceptably high incidence of morbidity and mortality.  (+info)

Perivalvular abscesses associated with endocarditis; clinical features and prognostic factors of overall survival in a series of 233 cases. Perivalvular Abscesses French Multicentre Study. (4/2034)

AIMS: The purposes of this study were to determine the clinical features and to identify prognostic factors of abscesses associated with infective endocarditis. METHODS AND RESULTS: During a 5-year period from January 1989, 233 patients with perivalvular abscesses associated with infective endocarditis were enrolled in a retrospective multicentre study. Of the patients, 213 received medical surgical therapy and 20 medical therapy alone. No causative microorganism could be identified in 31% of cases. Sensitivity for the detection of abscesses was 36 and 80%, respectively using transthoracic and transoesophageal echocardiography. Surgical treatment consisted of primary suture of the abscess (38%), insertion of a felt aortic or mitral ring using Teflon or pericardium (42%), or debridment of the abscess cavity (20%). The 1 month operative mortality was 16%. Actuarial rates for overall survival at 3 and 27 months in operated patients were 75 +/- 10% and 59 +/- 11%, respectively. Increasing patient age, staphylococcal infection, and fistulization of the abscess were found to be independent risk factors in both 1 month and overall operative mortality. Renal failure was a risk factor predictive of operative mortality at 1 month, whereas uncontrolled infection and circumferential abscess were regarded as risk factors predictive of overall operative mortality. CONCLUSION: The data determined prognostic factors of abscesses associated with infective endocarditis.  (+info)

Replacement of the aortic root in patients with Marfan's syndrome. (5/2034)

BACKGROUND: Replacement of the aortic root with a prosthetic graft and valve in patients with Marfan's syndrome may prevent premature death from rupture of an aneurysm or aortic dissection. We reviewed the results of this surgical procedure at 10 experienced surgical centers. METHODS: A total of 675 patients with Marfan's syndrome underwent replacement of the aortic root. Survival and morbidity-free survival curves were calculated, and risk factors were determined from a multivariable regression analysis. RESULTS: The 30-day mortality rate was 1.5 percent among the 455 patients who underwent elective repair, 2.6 percent among the 117 patients who underwent urgent repair (within 7 days after a surgical consultation), and 11.7 percent among the 103 patients who underwent emergency repair (within 24 hours after a surgical consultation). Of the 675 patients, 202 (30 percent) had aortic dissection involving the ascending aorta. Forty-six percent of the 158 adult patients with aortic dissection and a documented aortic diameter had an aneurysm with a diameter of 6.5 cm or less. There were 114 late deaths (more than 30 days after surgery); dissection or rupture of the residual aorta (22 patients) and arrhythmia (21 patients) were the principal causes of late death. The risk of death was greatest within the first 60 days after surgery, then rapidly decreased to a constant level by the end of the first year. CONCLUSIONS: Elective aortic-root replacement has a low operative mortality. In contrast, emergency repair, usually for acute aortic dissection, is associated with a much higher early mortality. Because nearly half the adult patients with aortic dissection had an aortic-root diameter of 6.5 cm or less at the time of operation, it may be prudent to undertake prophylactic repair of aortic aneurysms in patients with Marfan's syndrome when the diameter of the aorta is well below that size.  (+info)

Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. (6/2034)

OBJECTIVES: The purpose of this study was to assess the incidence of warfarin fetal complications and whether they are dose-dependent. BACKGROUND: Gravid patients with mechanical heart valves require long-term anticoagulant therapy. Controversy exists concerning the appropriate treatment of these patients. METHODS: Forty-three women on warfarin carrying out 58 pregnancies were studied. For each patient with full-term pregnancy a caesarian section was scheduled for the 38th week during brief warfarin discontinuation. Maternal and fetal complications were evaluated. Fetal complications were divided according to the warfarin dosage < or = 5 mg and > 5 mg necessary to keep an international normalized ratio (INR) of 2.5 to 3.5, and analyzed subsequently. RESULTS: A total of 58 pregnancies were observed: 31 healthy babies (30 full term, 1 premature) and 27 fetal complications (22 spontaneous abortions, 2 warfarin embryopathies, 1 stillbirth, 1 ventricular septal defect, 1 growth retardation) were recorded. Two maternal valve thromboses occurred. No fetal or maternal bleeding was observed during caesarian sections or premature vaginal delivery. Patients whose warfarin doses during pregnancy were > 5 mg had 22 fetal complications, whereas those taking a dose < or = 5 mg had only five fetal complications (p = 0.0001). For an increase of the warfarin dose there was a substantially increased probability of fetal complications (p < 0.0001; p < 0.7316). CONCLUSIONS: There is a close dependency between warfarin dosage and fetal complications. Patients on warfarin anticoagulation may be delivered by planned caesarian section at the 38th week while briefly interrupting anticoagulation.  (+info)

Acute renal failure following cardiac surgery. (7/2034)

BACKGROUND: Acute renal failure requiring dialysis (ARF-D) occurs in 1.5% of patients following cardiac surgery, and remains a cause of major morbidity and mortality. While some preoperative risk factors have been characterized, the influence of preoperative and intraoperative factors on the occurrence of ARF following cardiac surgery is less well understood. METHODS: Preoperative and intraoperative data on 2843 consecutive adult patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) from February 1, 1995 to February 1, 1997 were recorded and entered into a computerized database. Two definitions of renal failure were employed: (i) ARF defined as a rise in serum creatinine (Cr) of 1 mg/dl above baseline; and (ii) ARF-D defined as the development of ARF for which some form of dialytic therapy was required. The association between preoperative and intraoperative variables and the development of ARF was assessed by multivariate logistic regression. RESULTS: A total of 2672 of the 2844 patients underwent isolated coronary artery bypass grafting (CABG) surgery, the remaining 172 underwent valve surgery with or without bypass grafting. Of the CABG patients 7.9% developed ARF and 0.7% developed ARF-D. The mortality for patients who developed ARF was 14% (OR 15, P = 0.0001) compared with 1% among those who did not develop ARF. The mortality for CABG patients who developed ARF-D was 28% (OR 20, P = 0.0001) compared with 1.8% among those who did not require dialysis. Variables that were significantly associated with the development of ARF by multivariate analysis included: increased age, elevated preoperative serum Cr, duration of CPB, presence of a carotid artery bruit, presence of diabetes, reduced cardiac ejection fraction and increased body weight. Variables independently associated with ARF-D included serum Cr, duration of CPB, carotid artery bruit and presence of diabetes. The utility of these models for predicting the development of ARF and ARF-D was confirmed by bootstrapping techniques. Because of the small number of patients who underwent valve surgery, none of these variables were significantly associated with the development of ARF or ARF-D in this group of patients. CONCLUSION: The development of ARF or ARF-D is associated with a high mortality following CABG surgery. We have identified perioperative variables, which may be useful in stratifying risk for the development of ARF.  (+info)

The natural history of aortic valve disease after mitral valve surgery. (8/2034)

OBJECTIVES: The present study evaluates the long-term course of aortic valve disease and the need for aortic valve surgery in patients with rheumatic mitral valve disease who underwent mitral valve surgery. BACKGROUND: Little is known about the natural history of aortic valve disease in patients undergoing mitral valve surgery for rheumatic mitral valve disease. In addition there is no firm policy regarding the appropriate treatment of mild aortic valve disease while replacing the mitral valve. METHODS: One-hundred thirty-one patients (44 male, 87 female; mean age 61+/-13 yr, range 35 to 89) were followed after mitral valve surgery for a mean period of 13+/-7 years. All patients had rheumatic heart disease. Aortic valve function was assessed preoperatively by cardiac catheterization and during follow-up by transthoracic echocardiography. RESULTS: At the time of mitral valve surgery, 59 patients (45%) had mild aortic valve disease: 7 (5%) aortic stenosis (AS), 58 (44%) aortic regurgitation (AR). At the end of follow-up, 96 patients (73%) had aortic valve disease: 33 AS (mild or moderate except in two cases) and 90 AR (mild or moderate except in one case). Among patients without aortic valve disease at the time of the mitral valve surgery, only three patients developed significant aortic valve disease after 25 years of follow-up procedures. Disease progression was noted in three of the seven patients with AS (2 to severe) and in six of the fifty eight with AR (1 to severe). Fifty two (90%) with mild AR remained stable after a mean follow-up period of 16 years. In only three patients (2%) the aortic valve disease progressed significantly after 9, 17 and 22 years. In only six patients of the entire cohort (5%), aortic valve replacement was needed after a mean period of 21 years (range 15 to 33). In four of them the primary indication for the second surgery was dysfunction of the prosthetic mitral valve. CONCLUSIONS: Our findings indicate that, among patients with rheumatic heart disease, a considerable number of patients have mild aortic valve disease at the time of mitral valve surgery. Yet most do not progress to severe disease, and aortic valve replacement is rarely needed after a long follow-up period. Thus, prophylactic valve replacement is not indicated in these cases.  (+info)

OBJECTIVE: We sought to describe the results of transfemoral aortic valve implantation using either the Sapien prosthesis or the CoreValve System.. BACKGROUND: Results of transfemoral aortic valve implantation using both commercially available prostheses have rarely been studied.. PATIENTS: Of 236 patients at high-risk or with contraindications to surgery, consecutively referred for transcatheter aortic valve implantation between October 2006 and June 2009, 83 were treated with transfemoral aortic valve implantation. The Sapien was the only prosthesis available until May 2008 and, since then, was used as the first option, while the CoreValve System was used when contraindications to the Sapien prosthesis were present.. RESULTS: Patients were aged 81+/-9 years, 98% in New York Heart Association classes III/IV, with predicted surgical mortalities of 26+/-14% using the EuroSCORE and 15+/-8% using the Society of Thoracic Surgeons Predicted Risk of Mortality score. Seventy-two patients were treated ...
BACKGROUND New generation transcatheter heart valves (THV) may improve clinical outcomes of transcatheter aortic valve implantation. METHODS AND RESULTS In a nationwide, prospective, multicenter cohort study (Swiss Transcatheter Aortic Valve Implantation Registry, NCT01368250), outcomes of consecutive transfemoral transcatheter aortic valve implantation patients treated with the Sapien 3 THV (S3) versus the Sapien XT THV (XT) were investigated. An overall of 153 consecutive S3 patients were compared with 445 consecutive XT patients. Postprocedural mean transprosthetic gradient (6.5±3.0 versus 7.8±6.3 mm Hg, P=0.17) did not differ between S3 and XT patients, respectively. The rate of more than mild paravalvular regurgitation (1.3% versus 5.3%, P=0.04) and of vascular (5.3% versus 16.9%, P,0.01) complications were significantly lower in S3 patients. A higher rate of new permanent pacemaker implantations was observed in patients receiving the S3 valve (17.0% versus 11.0%, P=0.01). There were no ...
Get Transcatheter Aortic Valve Implantation cost from certified hospitals in Mumbai. Get assistance from medical experts to select best hospital for Transcatheter Aortic Valve Implantation in Mumbai
OBJECTIVES: The purpose of the present study was to test whether the cumulative knowledge from the field of transapical transcatheter aortic valve implantation, when incorporated into a structured training and then gradually dispersed by internal proctoring, might eliminate the negative effect of the learning curve on the clinical outcomes. METHODS: The present study was a retrospective, single-center, observational cohort study of prospectively collected data from all 500 consecutive high-risk patients undergoing transapical transcatheter aortic valve implantation at our institution from April 2008 to December 2011. Of the 500 patients, 28 were in cardiogenic shock. Differences during the study period in baseline characteristics, procedural and postprocedural variables, and survival were analyzed using different statistical methods, including cumulative sum charts. RESULTS: The overall 30-day mortality was 4.6% (95% confidence interval, 3.1%-6.8%) and was 4.0% (95% confidence interval, ...
TY - JOUR. T1 - Comparison of midterm outcomes of transcatheter aortic valve implantation in patients with and without previous coronary artery bypass grafting. AU - On behalf of the OCEAN-TAVI Investigators. AU - Kawashima, Hideyuki. AU - Watanabe, Yusuke. AU - Kozuma, Ken. AU - Kataoka, Akihisa. AU - Nakashima, Makoto. AU - Hioki, Hirofumi. AU - Nagura, Fukuko. AU - Nara, Yugo. AU - Shirai, Shinichi. AU - Tada, Norio. AU - Araki, Motoharu. AU - Naganuma, Toru. AU - Yamanaka, Futoshi. AU - Ueno, Hiroshi. AU - Tabata, Minoru. AU - Mizutani, Kazuki. AU - Higashimori, Akihiro. AU - Takagi, Kensuke. AU - Yamamoto, Masanori. AU - Hayashida, Kentaro. PY - 2018/4/21. Y1 - 2018/4/21. N2 - The midterm safety and feasibility of transcatheter aortic valve implantation (TAVI) for patients with a history of coronary artery bypass graft (CABG) and high operative risk are unclear. This study compared the midterm outcomes of patients undergoing TAVI with or without previous CABG surgery. Between October 2013 ...
TY - JOUR. T1 - Use of Double Stiff Wire Allows Successful Transfemoral Transcatheter Aortic Valve Implantation Through Extreme Thoracic Aorta Tortuosity. AU - Buzzatti, Nicola. AU - Mangieri, Antonio. AU - Cota, Linda. AU - Ruparelia, Neil. AU - Romano, Vittorio. AU - Alfieri, Ottavio. AU - Colombo, Antonio. AU - Montorfano, Matteo. PY - 2015/4/21. Y1 - 2015/4/21. KW - complication. KW - transcatheter aortic valve implantation. UR - http://www.scopus.com/inward/record.url?scp=84937484987&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84937484987&partnerID=8YFLogxK. U2 - 10.1161/CIRCINTERVENTIONS.114.002331. DO - 10.1161/CIRCINTERVENTIONS.114.002331. M3 - Article. C2 - 25794508. AN - SCOPUS:84937484987. VL - 8. JO - Circulation: Cardiovascular Interventions. JF - Circulation: Cardiovascular Interventions. SN - 1941-7640. IS - 4. M1 - e002331. ER - ...
Introduction Permanent pacemaker implantation (PPM) following transcatheter aortic valve implantation (TAVI) is a recognised complication. However, the higher pacing rate post CoreValve TAVI compared to SAVR (33% vs 8%) is a cause for concern. Several factors including pre-existing bundle branch block (BBB), larger valve size, post dilatation and low implantation have been shown to independently impact on an increased risk of PPM requirement. Depth of CoreValve implantation below the aortic annulus can result in compression of conduction tissue and heart block and is therefore an important predictor of PPM requirement. A modified delivery catheter (ACCUTRAK) was introduced to address this by providing more controlled release of the prosthesis, preventing low implantation, thereby reducing the pacing rate. We evaluated the pacing rate in our cohort of patients (pts) and the effect of the new Accutrak catheter on the pacing rate. ...
TY - JOUR. T1 - First in human percutaneous implantation of a balloon expandable transcatheter heart valve in a severely stenosed native mitral valve. AU - Guerrero, Mayra. AU - Greenbaum, Adam. AU - ONeill, William. PY - 2014/6/1. Y1 - 2014/6/1. N2 - Transcatheter implantation of a balloon expandable valve in calcified severely stenosed native mitral valves has recently been described. The two cases reported so far utilized the surgical transapical approach generally used for transapical transcatheter aortic valve replacement. A percutaneous approach has not been published. We report the first successful percutaneous implantation of a balloon expandable transcatheter valve in the native mitral valve without a surgical incision.. AB - Transcatheter implantation of a balloon expandable valve in calcified severely stenosed native mitral valves has recently been described. The two cases reported so far utilized the surgical transapical approach generally used for transapical transcatheter aortic ...
BACKGROUND: Transcatheter aortic valve implantation was developed to provide a therapeutic option for patients considered to be ineligible for, and to mitigate mortality and morbidity associated with, high-risk surgical aortic valve replacement.. METHODS AND RESULTS: The Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry was designed to assess initial post commercial clinical transcatheter aortic valve implantation results of the Edwards SAPIEN valve in consecutive patients in Europe. Cohort 1 consists of 1038 patients enrolled at 32 centers. One-year outcomes are presented. Patients with the transapical approach (n=575) suffered more comorbidities than transfemoral patients (n=463) with a significantly higher logistic EuroSCORE (29% versus 25.8%; P=0.007). These groups are different; therefore, outcomes cannot be directly compared. Total Kaplan Meier 1-year survival was 76.1% overall, 72.1% for transapical and 81.1% for transfemoral patients, and 73.5% of surviving patients ...
Background: Transfemoral access is regarded as the TAVI gold standard for the transcatheter aortic valve implantation (TAVI) procedure. However, other options for vascular access have developed in the last few years. Access via the carotid artery is one such alternative. Materials and methods: The study included 9 elderly patients who underwent transcarotid TAVI procedure at the Cardiac and Vascular Surgery Department of the Medical University of Gdańsk. Procedures were performed by a local Heart Team in a hybrid operating room under general anesthesia. Data was collected before the implantation and at discharge. Results: The mean patients age was 81 years of age (64-88) and the mean logistic EuroSCORE was 10.8 (7-16). Implantations were performed with 100% device success rate. Intra-operative valve-in-valve procedure was performed in one patient; there were no access-related and valve-related complications during the surgery. Post-procedural complications included minor bleeding, hematoma and ...
Vascular complications were a factor that tempered the enthusiasm of widespread adoption of transcatheter aortic valve replacement (TAVR) after the completion of the original PARTNER IB (The Placement of Aortic Transcatheter Valves IB) trial (1). In that trial, the rate of major vascular complications was 16.2%. This was not surprising given the need for a 22- or 24-F delivery sheath via a transfemoral approach only. This rate later decreased in a high risk cohort of patients (2). This was not only as a result of increased operator experience, but also because of the availability of an alternative access for patients with peripheral arterial disease. The transapical approach involved direct left ventricular puncture with placement of a 26-F delivery sheath, which allowed delivery of the valve. As TAVR became available commercially, additional access approaches were developed. The first of these, the transaortic approach, showed lower rates of combined bleeding and vascular events compared to a ...
A prospective multi-center trial of patients undergoing aortic valve replacement for severe aortic stenosis. Patient cohorts will include the following groups based on operative risk for surgical aortic valve replacement: inoperable, high surgical risk (STS ≥ 8%), and intermediate risk (STS = 4-8%).. The Edwards SAPIEN XT transcatheter heart valve (THV) system will be studied in patients deemed inoperable or intermediate risk. A subset of inoperable patients will be randomized to receive transcatheter aortic valve replacement (TAVR) with either the SAPIEN XT THV or the SAPIEN THV. The SAPIEN XT will be studied in intermediate risk patients randomized to receive TAVR with the SAPIEN XT or surgical AVR.. The Edwards SAPIEN 3 THV will be studied in a non-randomized fashion in patients from all three risk groups.. Data will be collected from all patients for up to five years following the valve replacement procedure. ...
A prospective multi-center trial of patients undergoing aortic valve replacement for severe aortic stenosis. Patient cohorts will include the following groups based on operative risk for surgical aortic valve replacement: inoperable, high surgical risk (STS ≥ 8%), and intermediate risk (STS = 4-8%).. The Edwards SAPIEN XT transcatheter heart valve (THV) system will be studied in patients deemed inoperable or intermediate risk. A subset of inoperable patients will be randomized to receive transcatheter aortic valve replacement (TAVR) with either the SAPIEN XT THV or the SAPIEN THV. The SAPIEN XT will be studied in intermediate risk patients randomized to receive TAVR with the SAPIEN XT or surgical AVR.. The Edwards SAPIEN 3 THV will be studied in a non-randomized fashion in patients from all three risk groups.. Data will be collected from all patients for up to five years following the valve replacement procedure. ...
Introduction: Readmission within 30 days of hospitalization (30dRA) is increasingly used as a metric for quality of care. Transcatheter aortic valve replacement (TAVR) is also increasing, but 30dRA following TAVR is not well-understood.. Hypothesis: The purpose of this study is to define the incidence, etiology, and resource utilization of 30dRA following TAVR.. Methods: We used the ICD-9-CM code for TAVR (35.05) to identify patients who underwent TAVR and survived to discharge in 2012, in the Agency for Healthcare Research and Qualitys Healthcare Cost and Utilization Projects State Independent Databases for 4 geographically distinct states: Florida, Massachusetts, New York, and Washington. The patients were divided into 2 groups: those with and without a 30dRA. Patients with a 30dRA for rehabilitation on the day of discharge were excluded. Approximately 8% of 30dRA were not captured because they occurred in the following year.. Results: The incidence of 30dRA following TAVR was 20.2% ...
To report the initial US experience with newly approved transcatheter aortic valve replacement, Mack and coauthors gathered outcome data, including all-cause in
The most frequent mechanism associated with coronary obstruction after TAVI has been the displacement of the calcified native cusp over the coronary ostium, and this has also been confirmed by the present review of the published data. In fact, no cases of coronary obstruction related to the struts of the transcatheter valve frame or to the cuff/leaflets of the transcatheter valve itself have been reported to date. Although the final mechanism leading to coronary obstruction after TAVI is well understood, the risk factors that predispose a patient to its occurrence remain largely unknown. A low position of the coronary ostia with respect to the aortic annulus has been highlighted as one of the most important factors contributing to this complication, and it has been suggested that a coronary ostia height cutoff ≤10 mm increases the risk of coronary obstruction during TAVI (41,42). In a recent post-mortem study, including 51 normal hearts, the mean LCA height, as determined by the LCA distance ...
The first-in-human transcatheter aortic valve implantation (TAVI) was successfully performed in 2002. In excess of 50,000 TAVI procedures have been performed to date using the Edwards SAPIEN or...
Advanced chronic kidney disease (CKD) is an independent predictor of mortality in patients undergoing transcatheter aortic valve implantation (TAVI). We aimed to identify predictors of 1-year mortality in patients after TAVI stratified by the presence or absence of advanced CKD (defined as estimated glomerular filtration rate ≤30 ml/min/1.73 m2 or permanent renal replacement therapy). Patients (n = 1204) from 10 centers in Europe, Japan, and Israel were included: 464 with and 740 without advanced CKD. Advanced CKD was associated with a 2-fold increase in the adjusted risk of 1-year all-cause death (p |0.001), and a 1.9-fold increase in cardiovascular death (p = 0.016). Interaction-term analysis was used to identify and compare independent predictors of 1-year mortality in both groups. Impaired left ventricular ejection fraction and poor functional class were predictive of death in the advanced CKD group (odds ratio [OR] 2.27, p = 0.002 and OR 3.87, p = 0.003, respectively) but not in patients without
The purpose of the study is to investigate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with severe,...
David H. Adams, MD, national co-principal investigator for the CoreValve U.S. Pivotal Trial, presented study results showing minimally invasive transcatheter aortic valve replacement (TAVR) with the CoreValve System is superior to surgical aortic valve replacement (SAVR) at one year in patients with severe aortic stenosis who are considered high risk for surgery.. Dr. Adams presented the findings at a late-breaking clinical trial session at the 63rd Annual Scientific Session of the American College of Cardiology (ACC), and also published simultaneously in the New England Journal of Medicine (NEJM).. The CoreValve High Risk Study is the first prospective, randomized study to show any transcatheter aortic valve to be superior to surgery. The CoreValve System was approved by the U.S. Food and Drug Administration (FDA) in January 2014 for patients considered extreme risk for surgery; the device is not currently approved in the U.S. for use with patients at high risk.. The head-to-head study met its ...
Philip F, Wong GB, Rogers JH, Low RI, Southard JA. Aortic Root and Annular Anatomical Exclusion for Transcatheter Aortic Valve Implantation. TCT Scientific Sessions. San Francisco, CA. November 11-15, 2015.. Wong GB, Southard JA, Rogers JH, Smith TW, Philip F, Singh G, Latif S, Boyd WD, Atkins B, Low RI. Heart Rate Variability of the Aortic Regurgitation Index Following Transcatheter Aortic Valve Replacement. SCAI 2015 Scientific Sessions. San Diego, CA May 6-10, 2015.. Sarcon A, Ghadri JR, Wong GB, Luscher TF, Templin C, Amsterdam EA. Takotsubo cardiomyopathy associated with opiate withdrawal. Q J Med. 2014; 107: 301-302.. Singh GD, Wong GB, Southard JA, Amsterdam EA. Food for thought: Atrioventricular dissociation. Am J of Medicine. 2013; 126(12): 1050-1053.. Wong GB, Southard J, Rogers J, Singh G, Smith T, Armstrong E, Flores M, Boyd D, Low R. Heart Rate Variability of the Aortic Regurgitation Index Following Transcatheter Aortic Valve Replacement. SCAI 2013 Scientific Sessions. Orlando, FL ...
If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patients written consent to publication and send them to the editorial office before submitting your response [Patient consent forms] ...
We sought to analyze outcomes of women receiving balloon-expandable valves (BEV) or self-expanding valves (SEV) in contemporary transcatheter aortic valve implantation (TAVI). WIN TAVI (Womens INternational Transcatheter Aortic Valve Implantation) is the first all-female TAVI registry to study the safety and performance of TAVI in women. We compared women treated with BEV (n = 408, 46.9%) versus those treated with SEV (n = 461, 53.1%). The primary efficacy end point was the Valve Academic Research Consortium-2 (VARC-2) composite of 1-year all-cause death, stroke, myocardial infarction, hospitalization for valve-related symptoms or heart failure or valve-related dysfunction. Women receiving SEV had higher surgical risk scores, higher rate of previous stroke and pulmonary hypertension whereas women receiving BEV were more frequently denied surgical valve replacement due to frailty. BEV patients were less likely to require post-dilation and had significantly lower rates of residual aortic ...
Transcatheter aortic valve replacement (TAVR) is an alternative to surgical aortic valve replacement for inoperable or surgical high-risk patients with severe aortic stenosis (1-3). Post-procedural aortic regurgitation (PAR) is a common complication after TAVR. PAR has been reported in 65% to 96% of TAVR cases (1,4-7). In most cases, the grade of regurgitation is usually only mild. However, moderate and severe grades of PAR occur in 2% to 24% of patients (1,4-7). Multiple studies have demonstrated that moderate and severe grades of PAR are associated with worse clinical outcomes (4,6). Furthermore, the 2-year follow-up of the PARTNER (Placement of Aortic Transcatheter Valves) trial has suggested that even mild paravalvular regurgitation has been associated with increased mortality (3). However, reliable methods to diagnose PAR severity have not been established.. The aortic regurgitation (AR) index is 1 of the valuable prognostic parameters for PAR in a catheterization laboratory (8). However, ...
RESULTS: Valve-in-valve procedures were performed in 365 patients (96 initial registry, 269 continued access patients). Mean age was 78.9 ± 10.2 years, and mean Society of Thoracic Surgeons score was 9.1 ± 4.7%. At 30 days, all-cause mortality was 2.7%, stroke was 2.7%, major vascular complication was 4.1%, conversion to surgery was 0.6%, coronary occlusion was 0.8%, and new pacemaker insertion was 1.9%. One-year all-cause mortality was 12.4%. Mortality fell from the initial registry to the subsequent continued access registry, both at 30 days (8.2% vs. 0.7%, respectively; p = 0.0001) and at 1 year (19.7% vs. 9.8%, respectively; p = 0.006). At 1 year, mean gradient was 17.6 mm Hg, and effective orifice area was 1.16 cm(2), with greater than mild paravalvular regurgitation of 1.9%. Left ventricular ejection fraction increased (50.6% to 54.2%), and mass index decreased (135.7 to 117.6 g/m(2)), with reductions in both mitral (34.9% vs. 12.7%) and tricuspid (31.8% vs. 21.2%) moderate or severe ...
Methods and Results-This multicenter, propensity score-matched study compared hemodynamics and early clinical outcomes in 246 patients with an aortic annulus area ,400 mm2 undergoing transcatheter aortic valve replacement with either a self-expanding transcatheter heart valve (Symetis ACURATE neo, n=129) or a balloon-expandable transcatheter heart valve (Edwards SAPIEN 3, n=117). The 1:1 propensity score matching resulted in 92 matched pairs. For ACURATE neo versus SAPIEN 3-treated patients, 30-day mortality (0.0% versus 1.0%), 1-year mortality (8.3% versus 13.3%), incidence of stroke (3.3% versus 2.2%), life-threatening bleeding (1.1% versus 1.1%), and major vascular complications (2.2% versus 6.5%), as well as pacemaker implantation rate (12.0% versus 15.2%), were similar. Paravalvular regurgitation ≥moderate was rare in both groups (4.5% versus 3.6%). The ACURATE neo presented lower mean transvalvular gradients (9.3 versus 14.5 mm Hg; P,0.001), larger indexed effective orifice areas (0.96 ...
Transcatheter heart valve implantation techniques recently have been developed. The basic principle is based on fixation of a pericardial xenograft in a low-profile nitinol or steel stent that can be crimped onto a catheter. Because of the low profile of the stent, excellent hemodynamic function of these devices may be achieved. Access to the heart is gained by using a transfemoral or a transapical approach. Experimental studies on different approaches have been performed (5,6), and clinical feasibility studies in selected high-risk patients have been conducted (7-9). Recently the concept of transcatheter transapical aortic valve implantation has been proven clinically (10).. All of these nonconventional approaches aim at treating high-risk patients with degenerative valve disease. To minimize the reoperative risk for failed xenografts, the VinV concept was developed. This VinV concept takes advantage of recently developed transcatheter valve implantation techniques as well as clinical ...
Implantation was successful in 30 of 31 cases (aortic annulus diameter 24.7 ± 1.5 mm); THV dislodgement necessitated valve-in-valve implantation in one patient. Post-procedural aortic regurgitation was none/trace in 28 of 31 and mild in 3 of 31 patients. During follow-up, two patients underwent valvular reinterventions (surgical aortic valve replacement for endocarditis, valve-in-valve implantation for increasing paravalvular regurgitation). All-cause mortality was 12.9% and 19.3% at 30 days and 6 months, respectively. In the remaining patients, a significant improvement in New York Heart Association class was observed and persisted up to 6 months after TAVI.. ...
Despite the promising short-term results of the PARTNER trials,7 31 long-term outcomes after TAVR remain an ongoing concern. For instance, 2 to 5 year follow-up analysis of the PARTNER 2 trial31 demonstrated a higher incidence of all-cause mortality in the TAVR cohort. Many have postulated that the underlying reasons may include the increased likelihood of structural valve degeneration and paravalvular leakage associated with TAVR. Consistent with this hypothesis, the TAVR cohort in the PARTNER 2 trial had a greater need for repeat intervention and valve-in-valve TAVR. Unfortunately, the PARTNER trials did not separately compare TAVR with miAVR (as the surgical arm was inclusive of all approaches); therefore, leaving an important gap in the literature.. In our pooled analysis, the 30-day all-cause mortality did not differ significantly between both groups; however, midterm mortality was significantly higher in the TAVR cohort. It should be noted that none of the included studies independently ...
(EMAILWIRE.COM, July 19, 2019 ) OG Analysis, a global market research firm, has announced the release of their Global Transcatheter Heart Valve: By Product (Transcatheter aortic valve replacement, Transcatheter mitral valve and Transcatheter pulmonary valve replacement), By Surgical approach (Transfemoral...
Although the original VARC standardized endpoint definitions were fundamentally useful and have been widely adopted, growing experience with TAVI studies has identified some definitions as ambiguous, of limited clinical utility, or in need of updating or extension (5,6,63,64). This need provided the rationale for a VARC-2 document with such improvements and additions. As was the case with the original VARC process, it should be emphasized that this consensus manuscript is not intended to be a guidelines document, but rather a practical tool to facilitate and inform clinical research in TAVI.. Current clinical trials are focusing more on intermediate risk patients, and more studies are comparing TAVI with surgical AVR. Therefore, it becomes increasingly important to identify those patients who benefit from either treatment. Specific risk categories have been defined to allow universal clinical study designs and outcome comparisons.. Changes and additions that have been applied to improve the ...
Transcatheter aortic valve replacement (TAVR) is increasingly performed in patients who are at high surgical risk for surgical aortic valve replacement. The frequency of coronary artery disease is as high as 70 percent in patients with severe aortic stenosis. It is routine practice to perform preoperative coronary angiography and PCI in patients for whom TAVR is planned. However, many patients require post-TAVR coronary angiography and intervention. Depending on the type of the percutaneous valve, this may not be as easy as it is in the absence of a percutaneous valve. In this tip of the month, we discuss nuances and tips and tricks that can be employed for coronary angiography in these patients ...
At a median follow-up of 183 days (63-365) and 144 days (56-365), 50 patients (22%) died and 75 patients (33%) experienced MACE. A threefold increase in the rates for death and MACE was observed in patients above the median (M2 vs. M1) of CA125 (5.2 vs. 1.6 per 10 person-years and 8.3 vs. 3.3 per 10 person-years, respectively; p for both < 0.001). In a multivariable analysis adjusted for logistic EuroSCORE, New York Heart Association (NYHA) functional class III/IV, and device success, baseline values of CA125 (M2 vs. M1) independently predicted death (hazard ratio [HR], 2.18; 95% confidence interval [CI], 1.11-4.26; p = 0.023) and MACE (HR, 1.77; 95% CI, 1.05-2.98; p = 0.031). In the longitudinal analysis, InCA125 as a time-varying exposure, was highly associated with both endpoints: HR, 1.47; 95% CI, 1.01-2.14; p = 0.043 and HR, 2.26; 95% CI, 1.28-3.98; p = 0.005, for death and MACE, respectively. ...
There has been a lot of conjecture that transcatheter aortic valve replacement (TAVR) may one day replace open-heart surgical aortic valve replacement (SAVR). However, after attending the American College of Cardiology (ACC) 2016 meeting, it is evident that change will come much sooner than anyone anticipated. Wow is really the key summary I can offer regarding the TAVR vs. SAVR data presented at ACC. Three key presentations were all positive for TAVR, showing it is at least equal or superior to surgery. This is not bad for a new technology with largely inexperienced operators being able to perform as well or better than cardiac surgeons with decades of experience.. The Partner 2A trial for the Sapien XT showed that the second-generation TAVR device was equal to surgery in intermediate-risk surgical patients. It was pointed out by experts in numerous ACC sessions that if the two techniques are equal, the minimally invasive method will usually win out as a new standard of care. The improved ...
Background: The presence of mitral regurgitation (MR) is an independent predictor of mortality after conventional aortic valve replacement for aortic stenosis. The predictive value of pre-procedural MR on clinical outcome after TAVI is unknown.. Methods: 3,195 consecutive patients were enrolled between January 2010 and October 2011 in 33 centres. MR was graded according to pre-procedural transthoracic echocardiography (TTE) as none/trivial (=0), mild (=1), moderate (=2), moderate-to-severe (=3), or severe (=4). The mean age was 82±7 years; 49% were female and mean logistic EuroSCORE was 21.9±14.3. Balloon (BE) and self-expendable (SE) devices were implanted in 66.9% and 33.1% of patients, respectively. Approaches were transarterial (transfemoral: 74.6%; subclavian: 5.8%), transapical (17.8%), and transaortic (1.8%).. Results: Pre-procedural TTE showed no MR in 32% of cases, a grade 1 MR in 46% of cases, a grade 2 MR in 20% of cases and a grade 3-4 in 2% of cases. Procedural success rate was ...
Philip Green, Suzanne V. Arnold, David J. Cohen, Ajay J. Kirtane, Susheel K. Kodali, David L. Brown, Charanjit S. Rihal, Ke Xu, Yang Lei, Marian C. Hawkey, Rebeca J. Kim, Maria C. Alu, Martin B. Leon, Michael J. Mack ...
Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following Transcatheter Aortic Valve Replacement.
Edwards Lifesciences Corp. said it invested $35 million to gain an exclusive right to buy privately held Corvia Medical Inc., which makes implants to treat heart failure. Tewksbury, Mass.-based Corvias InterAtrial Shunt Device is approved in the European Union to treat heart failure with preserved or mildly reduced ejection fraction. The device is undergoing clinical trials in the U.S. to seek approval from the U.S. Food and Drug Administration. Irvine, Calif.-based Edwards Lifesciences also acquired certain assets of Mitralign Inc. including intellectual property and associated clinical and regulatory experience.. Tewksbury, Mass.-based Mitralign makes devices to treat functional mitral and tricuspid regurgitation, which are diseases resulting from dysfunctional valves within the heart. Edwards Lifesciences, which is focused on making medical devices for heart diseases, did not disclose additional terms of the transactions. The company added that the transactions are not expected to impact its ...
Surgical Aortic Valve Replacement (SAVR) vs Transcatheter Aortic Valve Implantation (TAVI): Results Comparison for Prosthesis-Patient Mismatch (PPM) - adjusted outcomes, including mortality, heart failure (HF) rehospitalization, stroke, and quality of life, at 1 year Reporter: Aviva Lev-Ari, PhD, RN J Am Coll Cardiol. 2018 Sep 18. pii: S0735-1097(18)38287-1. doi: 10.1016/j.jacc.2018.09.001. [Epub ahead of print] Prosthesis-Patient […]…
TY - JOUR. T1 - Prognostic value of pre-procedural left ventricular strain for clinical events after transcatheter aortic valve implantation. AU - Suzuki-Eguchi, Noriko. AU - Murata, Mitsushige. AU - Itabashi, Yuji. AU - Shirakawa, Kosuke. AU - Fukuda, Memori. AU - Endo, Jin. AU - Tsuruta, Hikaru. AU - Arai, Takahide. AU - Hayashida, Kentaro. AU - Shimizu, Hideyuki. AU - Fukuda, Keiichi. PY - 2018/10/1. Y1 - 2018/10/1. N2 - Background Transcatheter aortic valve implantation (TAVI) is an alternative therapy for surgically highrisk patients with severe aortic stenosis (AS). Although TAVI improves survival of patients with severe AS, the mechanism of this effect remains to be clarified. We investigated the effects of TAVI on left ventricular (LV) function and identified the predictive parameters for cardiac events after TAVI. Methods and results We studied 128 patients with severe symptomatic AS who underwent TAVI. Echocardiographic assessments were performed before and after TAVI. In addition to ...
TY - JOUR. T1 - Imaging Guidance for Transcatheter Aortic Valve Replacement. T2 - Is Transoesophageal Echocardiography the Gold Standard?. AU - Xu, Bo. AU - Mottram, Philip M.. AU - Lockwood, Siobhan. AU - Meredith, Ian T.. PY - 2017/10/1. Y1 - 2017/10/1. N2 - Transcatheter aortic valve replacement (TAVR) is traditionally performed under cardiac imaging guidance. In the early TAVR experience, intra-procedural transoesophageal echocardiography (TOE) is recommended to guide device deployment, in the context of general anaesthesia (GA). Intra-procedural TOE imaging is particularly useful during TAVR deployment as a contrast-saving strategy for patients with renal impairment. Evidence has emerged recently demonstrating that in selected patients, transthoracic echocardiography (TTE) can be used to provide intra-procedural guidance for TAVR. Additionally, there is a growing body of evidence supporting the performance of TAVR using fluoroscopy alone, without additional cardiac imaging. This article ...
Transcatheter Heart Valve Replacement and Repair Market 2026 report includes Segment savvy top to the base assurance on the reason of a few portions clubbed with exhibit size checks and gauges to screen the essential territories of industry improvement in detail. Whats more, an official blueprint gives nuances of the entire report such that dynamic gathering can quickly and clearly get an idea of the establishment information, consolidating examination and fundamental ends.. The study enormously protects a wide analysis of the Transcatheter Heart Valve Replacement and Repair market focusing on the strengths, threats, weaknesses, and opportunities for the global Transcatheter Heart Valve Replacement and Repair Market. Therefore, the Transcatheter Heart Valve Replacement and Repair Market study determines the insights of the industry and selective comments from experts all over the world.. Get a Sample Copy of the Report at: http://www.researchreportcenter.com/request-sample/1523043 ...
Transcatheter aortic valve replacement (TAVR) Market - Global Industry Analysis, Size, Share, Trends and Forecast, 2014 - 2022 Transcatheter aortic valve replacement (TAVR) Market - - Market research report and industry analysis - 10925577
According to the latest market report published by Persistence Market Research titled Global Transcatheter Heart Valve Replacement & Repair Market: Global Industry Analysis and Forecast, 2016 - 2026, the global transcatheter heart valve replacement & repair market is projected to expand at a CAGR of 13.9% during the forecast period (2016-2026).. Request for Report [email protected]://www.persistencemarketresearch.com/samples/11167. Transcatheter heart valve replacement is a relatively non-invasive procedure to repair the damaged heart valves with bioprosthetic valves for treatment of valvular heart disease namely aortic stenosis and mitral regurgitation among geriatric population. It is an alternative approach to conventional open heart surgery, especially for extremely high risk patients. Transcatheter heart valve replacement & repair market was valued at US$ 1,605.5 Mn in 2015 and the revenue is expected to increase to US$ 6,701.5 Mn by 2026 at a CAGR of 13.9% over the forecast period.. The report ...
Methods and Results-Data were obtained using the national inpatient sample between the years 2011 and 2014. We used the International Classification of Diseases, Ninth Edition, Clinical Modification procedure codes 350.5 and 350.6 to identify patients undergoing transcatheter aortic valve replacement. Primary outcome of interest was in-hospital mortality. A 2-tailed P value ,0.01 was considered to denote statistical significance for all analyses. We identified 42 189 patients who underwent transcatheter aortic valve replacement between the years 2011 and 2014. Of these, 62.1% (n=26 229) had no CKD/ESRD, 33.7% (n=14 252) had CKD, and 4% (n=1708) had ESRD. Patients with CKD or ESRD had greater in-hospital mortality, hospital length of stay, hemorrhage requiring transfusion, and permanent pacemaker implantation (P,0.001). ...
BACKGROUND: Patients undergoing surgical aortic valve replacement (SAVR) are considered at high risk of infective endocarditis (IE). However, data on the risk of IE following transcatheter aortic valve replacement (TAVR) are sparse and limited by the lack of long-term follow-up as well as a direct comparison with patients undergoing SAVR.. OBJECTIVES: This study sought to investigate the long-term incidence of IE in patients undergoing TAVR and to compare the long-term risk of IE with patients undergoing isolated SAVR.. METHODS: In this nationwide observational cohort study, all patients undergoing TAVR and isolated SAVR from January 1, 2008, to December 31, 2016, with no history of IE and alive at discharge were identified using data from Danish nationwide registries.. RESULTS: A total of 2,632 patients undergoing TAVR and 3,777 patients undergoing isolated SAVR were identified. During a mean follow-up of 3.6 years, 115 patients (4.4%) with TAVR and 186 patients (4.9%) with SAVR were admitted ...
Repair of the Transcatheter aortic valve is a minimally invasive procedure. This technique is used without removing it to treat or restore old and damaged aortic valve. The technique used to insert a new valve to the place of the old aortic valve is called the Transcatheter aortic valve replacement system. Between the left atrium and the left ventricle is the mitral valve. Mitral valve disorder is a condition in which the valve ceases working properly, leading to abnormal blood flow. This abnormal blood flow can lead to diseases such as prolapse of the mitral valve and regurgitation of the mitral valve.. Renub Research latest study report Transcatheter Heart Valve Replacement Market, Volume, Share by Materials (Mechanical and Tissue) Position (Transcather Mitral Valve Replacement and Transcatheter Aortic Valve Replacement), Region (United States, Germany, China, France, Italy, Japan, Spain, United Kingdom, India and Brazil), Company Analysis provides a detailed and comprehensive insight of the ...
Transcatheter Aortic Valve Implantation has become an alternative treatment for elderly patients with severe aortic stenosis at risk of surgical aortic valve replacement
Currently, aortic valve replacement procedures require a sternotomy and use of cardiopulmonary bypass (CPB) to arrest the heart and provide a bloodless field in which to operate. A less invasive alternative to open heart surgery is transapical or transcatheter aortic valve replacement (TAVR), already emerging as a feasible treatment for patients with high surgical risk. The bioprosthetic valves are delivered via catheters using transarterial or transapical approaches and are implanted within diseased aortic valves. This paper reports the development of a new self-expanding stent for minimally invasive aortic valve replacement and its delivery device for the transapical approach under real-time magnetic resonance imaging (MRI) guidance. Made of nitinol, the new stent is designed to implant and embed a commercially available bioprosthetic aortic valve in aortic root. An MRI passive marker was affixed onto the stent and an MRI active marker to the delivery device. These capabilities were tested in ...
Thrombocytopenia is common after transcatheter aortic valve implantation (TAVI) and is associated with mortality and major complications, although the underlying mechanisms are unclear. This retrospective single-center study aimed to identify factors associated with the decrease in platelet count (DPC) after TAVI in Japanese patients. Patients with severe aortic valve stenosis who underwent transfemoral TAVI between March 2014 and August 2019 were grouped according to DPC values of | 50% or ≥ 50% (DPC = 100% × [baseline platelet count-nadir platelet count]/[baseline platelet count]). Multivariable logistic regression analysis was performed to identify factors associated with a DPC of ≥ 50%. Among the 131 patients who underwent transfemoral TAVI, 74 patients (56%) had a DPC of ≥ 50%, and 57 patients (44%) had a DPC of | 50%. Significant risk factors for a DPC of ≥ 50% were older age, lower body mass index (BMI), and use of balloon-expandable valves (BEV). The multivariable analysis revealed that
The hypothesis of this study was that local anesthesia with monitored anesthesia care (MAC) is not harmful in comparison to general anesthesia (GA) for patients undergoing Transcatheter Aortic Valve Implantation (TAVR). TAVR is a rapidly spreading treatment option for severe aortic valve stenosis. Traditionally, in most centers, this procedure is done under GA, but more recently procedures with MAC have been reported. This is a systematic review and meta-analysis comparing MAC versus GA in patients undergoing transfemoral TAVR. Trials were identified through a literature search covering publications from 1 January 2005 through 31 January 2013. The main outcomes of interest of this literature meta-analysis were 30-day overall mortality, cardiac-/procedure-related mortality, stroke, myocardial infarction, sepsis, acute kidney injury, procedure time and duration of hospital stay. A random effects model was used to calculate the pooled relative risks (RR) with 95% confidence intervals. Seven observational
Transcatheter aortic valve implantation for failing surgical aortic bioprosthetic valve: from concept to clinical application and evaluation (part 2). JACC Cardiovasc Interv. 2011 Jul; 4(7):733-42 ...
Edwards SAPIEN XT transcatheter heart valve with the NOVAFLEX+ delivery system. Indications: The Edwards SAPIEN XT transcatheter heart valve is indicated for use in patients with symptomatic heart disease due to either severe native calcific aortic stenosis or failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., Society of Thoracic Surgeons operative risk score ≥ 8% or at a ≥ 15% risk of mortality at 30 days).. Contraindications: The THV and delivery systems are contraindicated in patients who cannot tolerate an anticoagulation/antiplatelet regimen or who have active bacterial endocarditis or other active infections.. Warnings: Observation of the pacing lead throughout the procedure is essential to avoid the potential risk of pacing lead perforation. There is an increased risk of stroke in transcatheter aortic valve replacement ...
TCT-748 First Human Cohort Transcatheter Aortic Valve Implantations Of The Colibri Heart Valve, A Pre-Mounted, Pre-Packaged, Low Profile Ready for Use, Dry Valve In A 14 French Delivery System. Fifteen months of Follow Up ...
ABSTRACT: The optimal treatment for coronary artery disease in patients who are candidates for percutaneous aortic valve implantation (PAVI) remains unclear. The operating team should take into consideration that the symptoms of ischemic heart disease could be identical to those of severe aortic stenosis and that performing percutaneous coronary intervention (PCI) in these frail patients prior to, or following PAVI, is not trivial. We describe a patient with severe aortic stenosis and significant coronary artery disease who was treated during the same interventional session: PCI that was followed immediately by PAVI. We review the different treatment strategies for patients who are candidates for PAVI and have coronary artery disease, discuss the relative advantages of each approach, and propose an algorithm for their treatment. _______________________________________________. J INVASIVE CARDIOL 2009;21:E237-E241. Key words: PaceC elevation. Calcific aortic stenosis is associated with ...
Minimally invasive aortic valve replacement versus aortic valve replacement through full sternotomy: the Brigham and Womens Hospital experience
Predilatation has been historically considered a mandatory step before transcatheter aortic valve implantation (TAVI) since it facilitates valve crossing and prosthesis delivery, ensures optimal valve expansion and improves hemodynamic stability during valve deployment.
Adequate presentation of risks and benefits of medical therapies is essential to informed decision making by patients. Transcatheter aortic valve replacement (T
BACKGROUND: Aortic regurgitation (AR) is an important limitation of transcatheter aortic valve replacement (TAVR) with ill-defined predictors and unclear long term impact on outcomes. We sought to analyze currently published literature to establish t
Introduction The development of transcatheter aortic valve replacement (TAVR) can certainly be considered one of the most fascinating examples of successful translational research in medicine. Thanks to an outstanding partnership between multidisciplinary clinicians and engineers, we could move from concept to bench, bench to bedside, bedside to clinical feasibility trials, then on to larger clinical registries and evidence based trials, leading ultimately to a breakthrough technology with durable impact on the pattern of medical practice. This disruptive technology evoked scepticism and criticism in the beginning, but thanks to innumerable clinical trials and evidence based investigations, it is now widely accepted by the medical community and its acceptance is continuing to grow. In the last fourteen years, TAVR has been performed in around 300,000 patients in 65 countries and adoption is increasing by 40% year on year. The field of TAVR is rapidly evolving, with major
Trans-apical Transcatheter Aortic Valve Replacement in a Patient with Severe and Complex Left Main Coronary Artery Disease (LMCAD) Writer: Larry H Bernstein, MD, FCAP and Curator: Aviva Lev-Ari, PhD, RN Significant, defined as a greater than 50 percent narrowing, left main coronary artery disease (LMCAD) is found in 4 to 6 percent of all patients who…
This report provides in-depth analysis of the Global Transcatheter Aortic Valve Replacement (TAVR) Market in terms of value and segments. Also assesses the key opportunities in this (TAVR) Market and outlines the factors that are and will be driving the growth of the industry..
When you walk in the doors of Altru Health System, you are in the presence of people who care deeply about your well-being. Learn more about Transcatheter Aortic Valve Replacement (TAVR).
Valve replacement surgery has a high rate of success and a low risk of causing other problems if you are otherwise healthy. Although most people have successful outcomes, there is a risk of death and serious problems during surgery. Valve replacement surgery is high-risk for people who have a failing left ventricle and who have had a heart attack. About 5 or less out of 100 people who have valve surgery die.footnote 3. If you have severe aortic valve regurgitation or stenosis, the risks of not replacing the valve may be greater than the risks of surgery, unless you have other health problems that make surgery too dangerous.. Even if valve replacement surgery is a success, you may have problems after surgery, such as:. ...
One of our new heart treatments is the Transcatheter aortic valve replacement. It is one of the minimally invasive heart procedures. Find out more.
【 Essay on Transcatheter Aortic Valve Replacement 】for free from best writers of Artscolumbia ✅ Largest assortment of free essays ✅ Find what you need here!
Transfemoral aortic valve implantation (TAVI) is the most commonly adopted access for TAVI, as vascular injury and complication remain a concern that affects both procedural and clinical outcomes, so...
The valve-in-valve concept is an emerging therapeutic option for patients with degenerative failure of previously implanted xenografts. Reoperation of degenerated bioprostheses has a high mortality risk that increases with the age and associated comorbidities of the patients. The transcatheter valve-in-valve implantation does not need resternotomy or cardiopulmonary bypass, potentially reducing the morbidity and mortality risk. However, unlike the transcatheter implants in native valves, in the valve-in-valve procedures, the leaflets and calcified annulus are replaced with the rigid annulus of the xenograft. This requires accurate sizing of the transcatheter valve, currently available in 2 sizes. Therefore, 3-dimensional imaging techniques, particularly multi-detector row computed tomography (MDCT), may provide a more exact sizing of the host xenograft ring. We report a mitral valve-in-valve procedure in a 79-year-old female patient with previous aortic and mitral valve replacement (a 21-mm and ...
Aortic annular rupture is a potentially fatal complication after transcatheter aortic valve implantation with high mortality. Although it is quite rare and difficult to identify the mechanisms and predictors, prosthesis oversizing and massive calcification of the aortic annulus are thought to be a potential risk of this complication. A case presented here is an aortic annular rupture after transcatheter aortic valve implantation. Although the valve was not oversized, there were 2 severe calcifications of aortic annulus at nearby areas like twin icicles, thought to be a trigger of this potentially fatal complication.Aortic annular rupture is a potentially fatal complication after transcatheter aortic valve implantation with high mortality. Although it is quite rare and difficult to identify the mechanisms and predictors, prosthesis oversizing and massive calcification of the aortic annulus are thought to be a potential risk of this complication. A case presented here is an aortic annular ...
Bioprosthetic valves are increasingly used in preference to mechanical valves in open SAVR, as lifelong oral anticoagulation is not required and its attendant complications can be avoided. A recent study has shown similar long-term survival rates in patients with bioprosthetic and mechanical valves. However, patients with bioprosthetic valves require reoperations due to their limited durability and expected degeneration;(12) those undergoing such reoperations face increased surgical risk due to their more advanced age (compared with their age during the index SAVR) during the redo surgery and scarring in the non-virgin chest. Consequently, valve-in-valve TAVI appears to be an attractive, minimally invasive method of replacing the degenerated surgical aortic bioprosthesis without the need for a reoperation. Several small case series and a global registry have shown that it is a feasible and viable option for patients at high risk.(5-9). In our initial Asian experience of valve-in-valve TAVI in ...
Objectives. To describe short-term clinical and echocardiography outcomes in patients undergoing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). To explore patient selection criteria for treatment with TAVI. Design. TAVI patients (n = 45) were matched to SAVR patients (n = 45) with respect to age within +/- 10 years, sex and systolic left ventricular function. Results. TAVI patients were older, 82 +/- 8 versus 78 +/- 5 years (p = 0.005) and they had higher logEuroSCORE, 16 +/- 11% versus 8 +/- 4% (p andlt; 0.001). There were no significant differences in 30 days mortality, stroke and myocardial infarction. TAVI patients received less erythrocyte (53% vs. 78%, p = 0.03) and thrombocyte (7% vs. 27%, p = 0.02) transfusions. Postoperative atrial fibrillation was less common (18% vs. 60%, p andlt; 0.001) in the TAVI group. Paravalvular regurgitation was more common in TAVI patients (87% vs. 0%, p andlt; 0.001) and 27% had access site complications. Aortic ...
A SWOT Analysis of Transcatheter Heart Valve Replacement and Repair, Professional Survey Report Including Top Most Global Players Analysis with CAGR and Stock Market Up and Down. The global Transcatheter Heart Valve Replacement and Repair market research report is crafted with the concise assessment and extensive understanding of the realistic data of the global Transcatheter […]. ...
A SWOT Analysis of Transcatheter Heart Valve Replacement and Repair, Professional Survey Report Including Top Most Global Players Analysis with CAGR and Stock Market Up and Down. The global Transcatheter Heart Valve Replacement and Repair market research report is crafted with the concise assessment and extensive understanding of the realistic data of the global Transcatheter […]. ...
Press Release issued Feb 23, 2017: According to the latest market report published by Persistence Market Research titled Global Transcatheter Heart Valve Replacement & Repair Market: Global Industry Analysis and Forecast, 2016 - 2026, the global transcatheter heart valve replacement & repair market is projected to expand at a CAGR of 13.9% during the forecast period (2016-2026).
The Edwards SAPIEN 3 Transcatheter Heart Valve System and Edwards SAPIEN 3 Ultra Transcatheter Heart Valve System are indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a Heart Team, including a cardiac surgeon, to be appropriate for the transcatheter heart valve replacement therapy.. The Edwards SAPIEN 3 Transcatheter Heart Valve System and Edwards SAPIEN 3 Ultra Transcatheter Heart Valve System are indicated for patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic or mitral valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 8% at 30 days, based on the STS risk score and other clinical co-morbidities unmeasured by the STS risk calculator).. Contraindications (Who should not use): ...
... cochlear implantation MeSH E04.650.230 - dental implantation MeSH E04.650.410 - heart valve prosthesis implantation MeSH ... heart-lung transplantation MeSH E04.100.376.485 - heart valve prosthesis implantation MeSH E04.100.376.719 - myocardial ... heart-lung transplantation MeSH E04.928.220.410 - heart valve prosthesis implantation MeSH E04.928.220.520 - myocardial ... auditory brain stem implantation MeSH E04.650.200 - blood vessel prosthesis implantation MeSH E04.650.210 - breast implantation ...
"Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with ... "Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis. First human case ... When the valve is not inserted correctly, when there is incomplete sealing between the native heart valve and the stented valve ... Artificial heart valves are susceptible to bacterial infection; most bacteria that cause heart valve infections come from the ...
"Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis". Circulation. 106 (24): ... Alain Cribier, Who Pioneered Heart Valve Replacement with Catheter, Receives Texas Heart Institute's Ray C. Fish Award for ... Alain Cribier, Who Pioneered Heart Valve Replacement with Catheter, Receives Texas Heart Institute's Ray C. Fish Award for ... Alain Cribier, Who Pioneered Heart Valve Replacement with Catheter, Receives Texas Heart Institute's Ray C. Fish Award for ...
1971 Ionescu and others in Leeds, England, creates the first bovine pericardial heart valve and begins its implantation in ... Pericarbon pericardial Valve prosthesis: an experience based on the lessons of the past' Annals of Thoracic Surgery 71, S289- ... Mitoflow pericardial heart valves: A 7 year clinical experience' In: Bodnar E (Ed) Surgery for heart Valve Disease. Proceedings ... A short history of the introduction in clinical use of valves made of animal tissue for heart valve replacement in humans ...
The first implantation of the caged ball heart valve, developed by Drs. Dwight E. Harken and William C. Birtwell, was made on ... who had implanted in her a prosthesis, made of polyurethane and Dacron, and designed by Drs. Nina Braunwald and Andrew Morrow. ... Died: American opera singer Leonard Warren, 48, suffered a heart attack while performing at the Metropolitan Opera in New York ... The next day, a 44-year-old woman received the valve and made a full recovery eight weeks later. ...
... congenital heart disease, heart failure, and heart valve disease. The risks associated with cardiac catheterization are ... Further prostheses for mitral und tricuspid valve replacement are under development and certainly will be available within the ... 2008). Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association ... However, TAVI (transcatheter aortic valve implantation) has emerged as a valid alternative for patients in whom conventional ...
Heart transplantation (37.52) Implantation of total replacement heart system Artificial heart (37.6) Implantation of heart and ... Replacement of heart valve (35.3) Operations on structures adjacent to heart valves (35.4) Production of septal defect in heart ... Fitting of external prosthesis of penis Penlie prosthesis NOS (64.95) Insertion or replacement of non-inflatable penlie ... Operations on valves and septa of heart (35.0) Closed heart valvotomy (35.1) Open heart valvuloplasty without replacement (35.2 ...
Bloomfield, P. (2002-06-01). "Choice of heart valve prosthesis". Heart. 87 (6): 583-589. doi:10.1136/heart.87.6.583. PMC ... transcatheter aortic valve implantation). Rather than removing the existing valve, the new valve is pushed through it in a ... Aortic valve repair Artificial heart valve Valvular heart disease Minimally invasive cardiac surgery Pericardial heart valves ... There are two basic types of replacement heart valve: tissue (bioprosthetic) valves and mechanical valves. Tissue heart valves ...
Cardiovascular-related artificial organs are implanted in cases where the heart, its valves, or another part of the circulatory ... Simmons M, Montague DK (2008). "Penile prosthesis implantation: past, present and future". International Journal of Impotence ... The artificial heart is typically used to bridge the time to heart transplantation, or to permanently replace the heart in case ... without the removal of the heart itself. Besides these, lab-grown hearts and 3D bioprinted hearts are also being researched.[ ...
Bloomfield P (June 2002). "Choice of heart valve prosthesis". Heart. 87 (6): 583-9. doi:10.1136/heart.87.6.583. PMC 1767148. ... "Polymeric heart valves for surgical implantation, catheter-based technologies and heart assist devices". Biomaterials. 36: 6-25 ... An artificial heart valve is a one-way valve implanted into a person's heart to replace a heart valve that is not functioning ... The human heart contains four valves: tricuspid valve, pulmonary valve, mitral valve and aortic valve. Their main purpose is to ...
India's first mechanical heart valve developed by the institute has now crossed 1,50,000 implantations. The Chitra Blood Bag ... The well-known TTK Chitra Heart Valve Prosthesis has had over 150,000 successful implants. Efforts are on for the development ... and is credited with the development of India's first mechanical heart valve that has now crossed 1,50,000 implantations, with ... Kerala Heart Failure Registry, National Heart Failure Registry and Newborn Congenital Heart Disease Registry The Department ...
The technology behind the prosthesis". Archived from the original on 29 June 2013. "First-in-man implantation of CARMAT's ... In 2012, he received a heart transplant at age 71 after 20 months on a waiting list. Artificial heart valve Artificial cardiac ... An artificial heart is a device that replaces the heart. Artificial hearts are typically used to bridge the time to heart ... "Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy". 11 May 2017. "Implantation of Carmat's Artificial Heart ...
... it is also a serious and often fatal experience in mechanical heart valves. The selection of biomaterials for wear resistance ... In bioceramics, flaws influence the reliability and strength of the material during implantation and fabrication. There are a ... Although wear is commonly reported in orthopaedic applications such as knee and hip joint prostheses, ...
... valvular heart disease, angina pectoris, and atherosclerosis. Examples include the artificial heart, artificial heart valve, ... Simmons M, Montague D (2008). "Penile prosthesis implantation: past, present, and future". International Journal of Impotence ... and artificial heart valves, such as the Bjork-Shiley valve, all of which have caused FDA intervention. The consequences of ... Thus, heart valve failure is likely to threaten the life of the individual, while breast implant or hip joint failure is less ...
... surgery Bone cement Artificial ligaments and tendons Dental implants for tooth fixation Blood vessel prostheses Heart valves ... Surgical implantation of a biomaterial into the body triggers an organism-inflammatory reaction with the associated healing of ... The most widely used valve is a bileaflet disc heart valve or St. Jude valve. The mechanics involve two semicircular discs ... Such functions may be relatively passive, like being used for a heart valve, or maybe bioactive with a more interactive ...
The pulmonary valve then needs to be replaced by a heart valve prosthesis. A drawback of this method is that it can frequently ... Transcatheter aortic valve implantation using anatomically oriented, marrow stromal cell-based, stented, tissue-engineered ... The lack of durable heart valve prostheses for young patients has driven forward research in tissue engineering approaches for ... heart valves: technical considerations and implications for translational cell-based heart valve concepts. Eur J Cardiothorac ...
The shape of these valves do not mimic normal heart valves. Tissue heart valves are usually made from animal tissues, either ... or TAVI transcatheter aortic valve implantation delivers a prosthetic valve through a catheter. The choice between SAVR and ... A replaceable model of Cardiac Biological Valve Prosthesis. Front of thorax, showing surface relations of bones, lungs (purple ... It is one of the four valves of the heart and one of the two semilunar valves, the other being the pulmonary valve. The aortic ...
Simon similarly used SynerGraft decellularized pig valves for implantation in children; however, these valves widely failed as ... "Biodegradable polymer with collagen microsponge serves as a new bioengineered cardiovascular prosthesis". The Journal of ... Tissue engineered heart valves (TEHV) offer a new and advancing proposed treatment of creating a living heart valve for people ... Tissue engineered heart valves offer certain advantages over traditional biological and mechanical valves: Living valve - The ...
... and infections of permanent indwelling devices such as joint prostheses, heart valves, and intervertebral disc. The first ... 60-70% of hospital-acquired infections are associated with the implantation of a biomedical device. This leads to 2 million ... Biofilms often form on the inert surfaces of implanted devices such as catheters, prosthetic cardiac valves and intrauterine ... "Research on microbial biofilms (PA-03-047)". NIH, National Heart, Lung, and Blood Institute. 20 December 2002. Rogers A (2008 ...
In May 2017, the company acquired Symetis SA, a developer of minimally invasive transcatheter aortic valve implantation devices ... Four years later, in 2010, when moving its heart-rhythm business from its acquisition of Guidant, Boston Scientific eliminated ... textile vascular prostheses), EP Technologies (cardiac ablation controllers), MinTec (abdominal aortic aneurysm grafts), ... for $1.75 billion, expanding its electrophysiology and heart product portfolios (see Frank Baylis). In June 2022, the business ...
Such devices as valves for transcatheter aortic valve implantation (TAVI); biliary, tracheal, and rectal stent grafts ( ... Remote endoprosthetics of the aorta and iliac arteries with a self-fixing synthetic prosthesis]. In: [Topical issues of surgery ... including the heart, the aorta and its branches, and the renal, extracranial, intracranial, and pulmonary arteries. Volodos and ... The first-ever human implantation of the fabric-covered Z-stent was performed by Volodos on May 5, 1985, to treat iliac artery ...
Biological Tissue in Heart Valve Replacement, Butterworths, (1972), London, pages 467-513. Ionescu M I, Ross D N, "Heart Valve ... He began the clinical implantation of these valves in April 1969. This procedure of valve construction and implantation had ... Thamilarasan N, Griffin B, (2002), "Choosing The Most Appropriate Heart Operation and Prosthesis", Cleveland Clinic Journal of ... "Fascia Lata Heart Valves", In: Ionescu M I,Ross D N, Wooler G H, Eds. Biological Tissue in Heart Valve Replacement Butterworths ...
... the artificial left heart, so common today. Development of an aortic valve replacement Together with Donald N. Ross in London, ... 1958; 289: 257-66 Senning Å., Elmquist R. Construction and implantation of a pacemaker (8.10.1958), Second International ... a precursor of intra-arterial vascular prostheses, together with Dierk Maas, the various pacemaker electrodes together with ... The Senning-Crafoord heart-lung mashine, cited by Galletti P.P., Brecher G. A. Heart-Lung Bypass. New York & London, Grune & ...
... blood continues to flow from the heart through the aortic valve. In addition, blood flow bypasses the native valve and exits ... MRI of the heart following implantation of a left ventricular apico‐aortic conduit. Rofo 2007 Jun;179(6):566‐71 Vassiliades TA ... Templeton implanted prostheses similar to those originally described by Sarnoff in five patients with severe aortic valve ... AAC avoids the risk of leakage around a replacement heart valve (aortic insufficiency), a serious complication of alternate ...
Screw valves, unlike Quake and ice valves, maintain their level of flow restriction without power input, and are thus ideal for ... improve prostheses, and monitor clinical parameters. Microfabrication has led to the development of Michigan probes and the ... flexible substrates has led to the development of a cardiac patch that adheres to the curvilinear surface of the heart by ... while addressing problems of thick substrates causing damage during implantation and triggering foreign-body reaction and ...
Mechanical stimuli, such as pressure pulses seem to be beneficial to all kind of cardiovascular tissue such as heart valves, ... synthetic ophthalmic prosthesis. The first modern use of the term as recognized today was in 1985 by the researcher, ... prior to implantation significantly improves the performance of the created 3-D scaffolds. The achieved biocompatibility was ... Bioartificial heart: Doris Taylor's lab constructed a biocompatible rat heart by re-cellularising a de-cellularised rat heart. ...
... an abnormal narrowing of the aortic valve in the heart. Video-assisted minilaparotomy surgery Koon Ho Rha and Seung Choul Yang ... Stent implantation of left main coronary artery stenosis Park Seung-jung pioneered a new method using a stent as an alternative ... "Stretchable silicon nanoribbon electronics for skin prosthesis". Nature Communications. 5: 5747. Bibcode:2014NatCo...5.5747K. ... "Innovator of alternative heart surgery". The Korea Times. 29 November 2015. Retrieved 3 April 2017. "AUA2016 Annual Meeting". ...
... occurs when the mitral valve allows reversal of blood flow from the left ventricle (LV) to the left atrium. The presentation of ... Use of mitral homograft to support a mechanical valve prosthesis: a feasible solution for recurrent mitral valve dysfunction. J ... Mitral valve surgery for rheumatic lesions in young patients. World J Pediatr Congenit Heart Surg. 2016 May. 7(3):321-8. [QxMD ... Which Patients With Aortic Stenosis Should Be Referred to Surgery Rather Than Transcatheter Aortic Valve Implantation? ...
Heart failure develops when the heart, via an abnormality of cardiac function (detectable or not), fails to pump blood at a ... Orban M, Hausleiter J. Edge-to-edge mitral valve repair: solid data and a prosperous future. Heart. 2018 Feb. 104(4):280-1. [ ... Orthotopic cardiac prosthesis for two-staged cardiac replacement. Am J Cardiol. 1969 Nov. 24 (5):723-30. [QxMD MEDLINE Link]. ... Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for ...
... and underwent aortic valve replacement in our clinic were examined retrospectively. Results: Preoperative effort capacities of ... and 6 biologic aortic valves were used. Postoperative hospital mortality was recorded as 12% with 4 patients. Patients were ... Hypertension; Heart Valve Prosthesis Implantation; Prognosis 1. INTRODUCTION Cases with aortic valve area below 0.6 cm2/m2 are ... artery pressure on aortic valve replacement* Faruk Toktas1, Arif Gucu1, Gunduz Yumun1, Cuneyt Eris1, Serhat Yalcinkaya2, Mehmet ...
heart valve prosthesis implantation. *quality of healthcare. *outcome assessment. *healthcare. *aortic valve stenosis ... transcatheter aortic valve implantation (TAVI): the TASQ registry. Open Heart 2019;6:e001008. doi:10.1136/openhrt-2019-001008 ... Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research Consortium-2 ... Aortic valve replacement: validation of the Toronto aortic stenosis quality of life questionnaire. ESC Heart Fail 2021;8:270-9. ...
keywords = "Aortic Valve/Surgery, Heart Valve Prosthesis Implantation, Heart Valve Prosthesis/ Utilization", ... 139 received a Perceval S sutureless valve (Group A) and 624 received a Perimount Magna Ease valve (Group B). These groups were ... 139 received a Perceval S sutureless valve (Group A) and 624 received a Perimount Magna Ease valve (Group B). These groups were ... 139 received a Perceval S sutureless valve (Group A) and 624 received a Perimount Magna Ease valve (Group B). These groups were ...
Until recently, surgical aortic valve replacement has been the standard of care in adults with severe symptomatic aortic ... Prosthesis-patient mismatch after transcatheter aortic valve implantation with the Medtronic-CoreValve bioprosthesis. Eur Heart ... Aortic valve prosthesis-patient mismatch and exercise capacity in adult patients with congenital heart disease. Heart. January ... Prosthesis-patient mismatch predicts structural valve degeneration in bioprosthetic heart valves. Circulation. May 18, 2010;121 ...
Transcatheter Aortic Valve Replacement, Heart Valve Prosthesis Implantation, Risk Assessment, Heart Valve Prosthesis, Humans, ... surgical aortic valve replacement, transcatheter aortic valve implantation, transcatheter aortic valve replacement, ... Valve Academic Research Consortium 3 : Updated Endpoint Definitions for Aortic Valve Clinical Research. / VARC-3 WRITING ... title = "Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research", ...
Prosthesis Implantation, Heart Valve Prosthesis, 51876, Intensive Care Units, Therapeutics, Diagnostic Techniques, Neurological ... Heart Septal Defects, Atrial, Integumentary System, Intensive Care, Neonatal, Pulmonary Valve, Heart Defects, Congenital, ... Heart Diseases, Shock, Cardiogenic, Resuscitation, Respiration, Artificial, Heart Massage, Cardiopulmonary Resuscitation, ... Cardiology, Heart, Diagnostic Techniques, Cardiovascular, Hypertension, Intracranial Hemorrhage, Hypertensive, Public Health, ...
Heart Valve Prosthesis. Heart Valve Prosthesis Implantation. Humans. Mitral Valve -- surgery. Postoperative Complications -- ... Long-term durability of three mechanical valves.. par De Smet, Jean-Marie ;Stefanidis, Constantin ;Antoine, Martine ;Primo, ...
Heart Valve Prosthesis Implantation. -. dc.subject.mesh. Humans. -. dc.subject.mesh. Hypertension, Malignant --complications. - ... Case 1 had an artificial mitral valve implant. Polycythemia and malignant hypertension were noted in Case 2. The third patient ... Heart Valve Diseases --surgery. -. dc.subject.mesh. ...
Heart valve prosthesis implantation kit (physical object). Code System Preferred Concept Name. Heart valve prosthesis ...
HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.. Annotation:. coordinate with specific ... HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use. ... The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; ... The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; ...
Aortic Valve Stenosis. *Transcatheter Aortic Valve Replacement. *Heart Valve Prosthesis. *Heart Valve Prosthesis Implantation ... Transcatheter aortic valve implantation (TAVI) for patients with symptomatic severe aortic stenosis. Agency for Care ... www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidances/details/transcatheter-aortic-valve-implantation-(tavi)-for ...
Heart Valve Prosthesis Implantation71 Lingua. * eng12428 * ita2075 * spa34 ...
Keywords: Aortic Valve Insufficiency/diagnostic imaging; Angiography/evaluation; Heart Valve Prosthesis Implantation; ... Balloon post-dilatation (BPD) is often needed for optimizing transcatheter heart valve (THV) implantation, since paravalvular ... Comparison of valve performance of the mechanically expanding Lotus and the balloon-expanded SAPIEN3 transcatheter heart valves ... Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 ...
Filters: Keyword is Heart Valve Prosthesis Implantation / *trends [Clear All Filters]. 2010 ... Barron DJ, Khan NE, Jones TJ, Willets RG, Brawn WJ. What tissue bankers should know about the use of allograft heart valves. ...
... of mechanical heart valves, 2% of breast implants, and 2% of joint prostheses are affected by biofilm infections [57]. ... voice prostheses), the microorganisms can be introduced during implantation of a prosthesis or derived from a transient ... Considering medical device infections (e.g., contact lenses, mechanical heart valves, peritoneal dialysis catheters, prosthetic ... joint prostheses, cardiac valves, artificial vascular bypass devices, pacemakers, ventricular assist devices, and central ...
Heart Valve Prosthesis. *Cardiovascular Surgical Procedures. *Thoracic Surgery. *Heart Valve Prosthesis Implantation ... Coronary artery bypass surgery on a beating HEART without a CARDIOPULMONARY BYPASS (diverting the flow of blood from the heart ... On-pump beating-heart coronary artery bypass grafting in high-risk patients: A systematic review and meta-analysis. J Card Surg ...
Risk factors for pacemaker implantation following aortic valve replacement: a single centre experience. Heart. 2003;89 (8):901- ... disorders and permanent pacemaker implantation after percutaneous aortic valve implantation with the CoreValve prosthesis. Am. ... Predictors for new-onset complete heart block after transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2010;3 (5) ... Postprocedural atrial fibrillation after transcatheter aortic valve implantation versus surgical aortic valve replacement. The ...
Heart Valve Prosthesis Implantation * Humans * Mitral Valve * Mitral Valve Insufficiency * Papillary Muscles ...
Key words: aortic stenosis, TAVI, valve-in-valve transcatheter aortic valve implantation, adult congenital heart disease ... Under pressure: The first valve-in-valve transcatheter aortic valve implantation for stenosis of a BioValsalva prosthesis using ... Under pressure: The first valve-in-valve transcatheter aortic valve implantation for stenosis of a BioValsalva prosthesis using ... Keywords: aortic stenosis, TAVI, valve-in-valve transcatheter aortic valve implantation, adult congenital heart disease ...
Aortic Valve Stenosis. *Heart Valve Prosthesis Implantation. *Medicare. See all (199) concept(s) ... Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement: Results From the Transcatheter Valve ... Trends in Cerebral Embolic Protection Device Use and Association With Stroke Following Transcatheter Aortic Valve Implantation ... Cardiac Noninvasive Diagnostic Testing for Outpatient Chest Pain: Rethinking "Less Is More". J Am Heart Assoc. 2020 07 07; 9(13 ...
... of prosthesis dislodgement after transcatheter mitral valve replacement in an 85-year-old woman with chronic ischaemic heart ... Background: LVAD implantation is increasingly used in patients with end-stage heart failure. Early VAs may occur during the 30- ... Carcinoid heart disease is a rare condition affecting mostly tricuspid and pulmonary valves causing right-sided heart failure. ... Surgical valve replacement is the mainstay of treatment when patients become symptomatic and/or in the presence of right heart ...
... of transcatheter valve-in-valve implantation of Sapien 3 and MyVal in degenerated biological tricuspid prosthesis valves. / ... European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American ... European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American ... European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American ...
... patients due to worsening heart failure. Conclusions: TAVR in patients with previous mitral prostheses appears to be safe and ... Outcome of Patients Undergoing Transcatheter Implantation of Aortic Valve With Previous Mitral Valve Prosthesis (OPTIMAL) Study ... Outcome of Patients Undergoing Transcatheter Implantation of Aortic Valve With Previous Mitral Valve Prosthesis (OPTIMAL) Study ... Outcome of Patients Undergoing Transcatheter Implantation of Aortic Valve With Previous Mitral Valve Prosthesis (OPTIMAL) Study ...
Heart Valve Prosthesis Implantation. *Aortic Valve Stenosis. *Blood Vessel Prosthesis. *Transcatheter Aortic Valve Replacement ...
"First human case of retrograde transcatheter implantation of an aortic valve prosthesis.." Tex Heart Inst J. 2005 32 (3): 393-8 ... First retrograde percutaneous heart valve in the world. Implanted the first retrograde percutaneous heart valve in the world.. ... "Establishment of a transcatheter aortic valve program and heart valve team at a Veterans Affairs facility.." Am. J. Surg.. 2012 ... Percutaneous heart valve in the chronic in vitro testing model.." Circulation.2002/September17;106(12):e51-2. Pubmed PMID: ...
Aortic valve replacement (AVR) may normalize flow patterns and potentially slow the concomitant aortic dilation. We therefore ... 30 BAV patients with a native aortic valve and 30 healthy subjects. RESULTS: The majority of subjects with mechanical AVR or ... Abnormal aortic flow patterns in bicuspid aortic valve disease (BAV) may be partly responsible for the associated aortic ... Heart Valve Diseases, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Hemodynamics, Humans, Image Interpretation, ...
Recently, at the Heart Institute, a transfemoral (implantation) implantation of the last-generation prosthesis of the aortic ... Endovascular implantation of the aortic valve was the only opportunity to save the patients life.. A few days ago the patient ... Transcatheter Aortic Valve Implantation on 84-Year-Old Patient. July, 13, 2018 ... New Heart Beats in the Chest of a 53-Year-Old Woman from Volyn ... Mini Mechanical Heart Implantation at the Heart Institute. * ...
Angielskie s owa kluczowe: Heart valve prosthesis - adverse effects ; Heart valve prosthesis implantation ; Mitral valve - ... Tytu angielski: Recurrent thrombosis of a mitral mechanical heart valve prosthesis during puerperium - a case report.. ... Heart rate - drug effects ; Blood flow velocity - drug effects ; Platelet aggregation - drug effects ; Fibrinolysis - drug ...
Heart Valve Prosthesis. Heart Valve Prosthesis Implantation. Humans. Male. Quality of Life. Retrospective Studies. Surveys and ... and aortic valve re-intervention rates were similar between groups, although mechanical valve patients had more bleeding events ... Impact of Valve Type (Ross vs. Mechanical) on Health-Related Quality of Life in Children and Young Adults with Surgical Aortic ... BACKGROUND: The impact of aortic valve replacement (AVR) type on health-related quality of life (HRQOL) in adolescents and ...
  • A heart team comprising cardiac surgeons, interventional cardiologists, and other aortic stenosis experts may determine what the best procedure is as well as take into account other considerations such as whether the patient should receive a mild sedative or general anesthesia. (medscape.com)
  • New definitions or modifications of existing definitions are being proposed for repeat hospitalizations, access site-related complications, bleeding events, conduction disturbances, cardiac structural complications, and bioprosthetic valve dysfunction and failure (including valve leaflet thickening and thrombosis). (houstonmethodist.org)
  • The patient had a complex cardiac surgical history in the setting of congenital heart disease - an atrial septal defect and bicuspid aortic valve. (hvt-journal.com)
  • At last follow-up, clinical outcomes including cardiac function, functional class, and aortic valve re-intervention rates were similar between groups, although mechanical valve patients had more bleeding events (p = 0.012). (mcw.edu)
  • I work with my colleagues in pulmonary and cardiac medicine to create personalized treatment plans for patients with advanced lung and heart diseases. (osu.edu)
  • 3D printing for cardiac device implantations (valvular prosthesis, ASD, congenital heart disease) in Cooperation with: Ao. (tirol-kliniken.at)
  • Vinod Thourani , associate professor of cardiac surgery at Emory School of Medicine, along with Jorge Jimenez and Ajit Yoganathan , biomedical engineers at Georgia Tech and Emory, have been teaming up to invent new devices for making heart valve repair easier. (emoryhealthsciblog.com)
  • Second-degree atrioventricular (AV) block, or second-degree heart block, is a disease of the cardiac conduction system in which the conduction of atrial impulse through the AV node and/or His bundle is delayed or blocked. (medscape.com)
  • Recently, specialists from the Department of Pediatric Cardiology and Congenital Heart Diseases together with the colleagues from the Departments of Cardiac Surgery and Radiology at the Medical University of Gdańsk in Poland have successfully introduced a new procedure. (zortrax.com)
  • American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young. (qscience.com)
  • In procedures where the aortic valve replacement (AVR) is combined with a coronary artery bypass graft (CABG), the use of a rapid deployment valve can shorten the duration of cardiac ischemia and the overall intervention duration, which possibly has an influence on clinical results. (clinicaltrials.gov)
  • VD-AR after THV implantation provides a quantitative assessment of post-TAVI regurgitation and can help in the decision-making process on performing BPD and in determining its efficacy. (sanarmed.com)
  • This case describes to our knowledge, the first successful balloon expandable valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for stenosis of a BioValsalva stentless aortic graft in a patient with complex congenital heart disease and two prior sternotomies. (hvt-journal.com)
  • Transcatheter aortic valve implantation (TAVI) is now routinely used for the management in aortic stenosis. (hvt-journal.com)
  • With growing experience with TAVI technology there has been an increase in the application of TAVI procedures including valve-in-valve (ViV) procedures. (hvt-journal.com)
  • TAVI in patients with adult congenital heart disease (ACHD) is not well described. (hvt-journal.com)
  • The aim of this case report is to describe the successful use of ViV-TAVI in a patient a patient with complex congenital heart disease, and to highlight challenges in the pre-procedure planning and procedure itself, particularly in the context of a stentless graft. (hvt-journal.com)
  • Als eine der ersten Arbeitsgruppen weltweit beschrieben wir die neue Entität der subklinischen thrombotischen Auflagerungen (so genannte „HALTs": hypo-attenuated leaflet thickening) früh nach TAVI-Implantation. (uniklinik-freiburg.de)
  • The proximity of the aortic valve to the conduction pathways (possible injury as a result from interventional equipment interactions) as well as the anatomical variants of AV nodes may predispose patients who underwent TAVI to higher risk of conduction abnormalities. (imedpub.com)
  • The Portico TM with FlexNav TM TAVI system is a minimally invasive treatment for patients with aortic valve stenosis. (structuralheart.abbott)
  • In the past, there has not been an accurate way to calculate mortality risk for patients with atrial fibrillation (AF) who have undergone a successful transcatheter aortic valve implantation (TAVI) and have been discharged home. (ctsnet.org)
  • Substantial progress in the field of cardiology has been achieved in the form of the breakthrough innovation transcatheter aortic valve implantation (TAVI). (uni-rostock.de)
  • Currently available devices in the United States include the self-expandable Evolut R and Evolut PRO valves, the balloon-expandable Sapien3 and Sapien 3 Ultra valves, and the mechanically-expandable Lotus Edge valve. (medscape.com)
  • Outcomes in patients with contained ruptures of the aortic annulus after transcatheter aortic valve implantation with balloon-expandable devices. (uniklinik-freiburg.de)
  • Among risk factors for LBBB development we can underline the self-expandable prostheses (in comparison with balloon-expandable ones) and larger implant depth. (imedpub.com)
  • We decided to leave the apicoaortic conduit intact and perform transcatheter aortic valve replacement with a balloon-expandable prosthesis. (allenpress.com)
  • There are a number of known artificial valves and a number of known methods of implanting these artificial valves in humans. (justia.com)
  • Percutaneous pulmonary valve implantation in humans: results in 59 consecutive patients. (bmj.com)
  • Reasons for nonadherence to guidelines for aortic valve replacement in patients with severe aortic stenosis and potential solutions. (uchicago.edu)
  • Mitral valve dynamics in severe aortic stenosis before and after aortic valve replacement. (uchicago.edu)
  • interquartile range [IQR], 77-85 years) presenting with severe aortic stenosis of the native valve and scheduled to undergo TAVR were enrolled. (thecardiologyadvisor.com)
  • To examine the impact of AF on the incidence of and indications for pacemakers in patients undergoing TAVR, we evaluated data of 1723 patients without pre-existing pacemakers who underwent TAVR in the Placement of AoRTic TraNscathetER Valve (PARTNER) trial. (jafib.com)
  • She underwent redo aortic valve replacement (AVR) with 25mm Biovalsalva stentless bioprosthetic valve, and replacement of the ascending aorta and transverse arch with a 26mm Dacron graft. (hvt-journal.com)
  • Methods: This is a retrospective registry of 154 patients with previous MV prostheses who underwent TAVR across high-volume medical centres at a mean of 11.7 ± 8.4 years after mitral surgery. (elsevier.com)
  • METHODS: Ninety participants underwent 4D flow cardiovascular magnetic resonance: 30 BAV patients with prior AVR (11 mechanical, 10 bioprosthetic, 9 Ross procedure), 30 BAV patients with a native aortic valve and 30 healthy subjects. (ox.ac.uk)
  • RESULTS: 143 patients (101 coronary and 42 structural) underwent procedures (coronary angiography, percutaneous coronary intervention, transcatheter aortic valve intervention and MitralClip) during the study period. (bvsalud.org)
  • A 67-year-old man with a history of chest radiotherapy and severe aortic valve stenosis with calcification of the ascending aortic wall underwent implantation of an apicoaortic conduit from the left ventricular apex to the descending aorta. (allenpress.com)
  • A total of 455 patients underwent a complete ARR with a bioprosthetic valve implant for nonendocarditis reasons, of which 212 (46.6%) received a stented valve, while 243 (53.4%) received a stentless valve. (semthorcardiovascsurg.com)
  • Despite increased survival, these patients often require surgery at a young age and are susceptible to developing complications related to the degeneration of surgical prostheses and valves. (hvt-journal.com)
  • The investigators describe the successful transfemoral positioning of a 29-mm Edwards SAPIEN XT percutaneous valve inside the degenerated tricuspid prosthesis, with excellent acute results and no major complications. (ajconline.org)
  • We can distinguish several factors that have the evident impact on previously described complications, such as: pre-existing RBBB, type of the transcatheter valve, annular size, depth of the implantation and the degree of mitral and aortic valve calcifications. (imedpub.com)
  • What are the complications of prosthetic valves? (syrianclinic.com)
  • After those events, the aortic arch prosthesis was replaced without further complications. (cdc.gov)
  • Our goal is, through biofunctionalization, to prevent the infections associated with cardiovascular implants, especially heart valve prostheses, and to improve the diagnosis and treatment of these life-threatening complications. (uni-rostock.de)
  • The human heart can suffer from various valvular diseases. (justia.com)
  • These valvular diseases can result in significant malfunctioning of the heart and ultimately require replacement of the native valve with an artificial valve. (justia.com)
  • Due to aortic stenosis and other heart valve diseases, thousands of patients undergo surgery each year wherein the defective native heart valve is replaced by a prosthetic valve, either bioprosthetic or mechanical. (justia.com)
  • The HF clinic route based on the HF etiology and the underlying diseases responsible for HF could become an interesting approach, compared with the traditional programs, mainly based on non-specific HF subtypes and New York Heart Association class, rather than on detailed etiologic and epidemiological data. (bvsalud.org)
  • This is the first FET prosthesis commercially available in the US and will bring a new viable treatment option for patients with diseases of the aortic arch and descending aorta. (ctsnet.org)
  • Diseases of the heart are among the most common in the population and represent a serious health risk. (uni-rostock.de)
  • Balloon post-dilatation (BPD) is often needed for optimizing transcatheter heart valve (THV) implantation, since paravalvular leak (PVL) after transcatheter aortic valve implantation is associated with poor outcome and mortality. (sanarmed.com)
  • Long term outcome of mechanical valve prosthesis in the pulmonary position. (bmj.com)
  • Outcome of right ventricular assist device implantation following left ventricular assist device implantation: Systematic review and meta-analysis. (unibas.ch)
  • In this study, we evaluated health status outcomes, based on the TASQ, in patients with severe AS undergoing transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). (bmj.com)
  • Transcatheter aortic valve replacement (TAVR) was developed as an alternative to the surgical approach in this high-risk and inoperable population. (medscape.com)
  • TAVR is a minimally invasive, catheter-based procedure to replace the function of the aortic valve. (medscape.com)
  • Indicated for patients at intermediate or greater risk for open heart surgery, TAVR may be an excellent option for certain patients because the prevalence of aortic stenosis and comorbidities may increase the risks associated with surgical aortic valve replacement (SAVR). (medscape.com)
  • No established indications or guidelines exist yet for transcatheter aortic valve replacement (TAVR) in the United States. (medscape.com)
  • There are few data examining pacemaker implantation rates and indications in patients with AF who undergo transcatheter aortic valve replacement (TAVR). (jafib.com)
  • In conclusion, conversion to AF is an independent predictor of permanent pacemaker implantation in TAVR patients. (jafib.com)
  • 1 ]-[ 4 ] As the clinical adoption of transcatheter aortic valve replacement (TAVR) has increased, there has been particular interest in the clinical implications of post-TAVR arrhythmias and conduction abnormalities. (jafib.com)
  • Recent studies have shown that rates of PPM after TAVR range from approximately 6 to 11.5% with the Edwards SAPIEN Valve (Edwards LifeSciences, Irvine, CA)[ 13 ]-[ 15 ] and 15 to 33.3% with the Medtronic CoreValve (Medtronic, Minneapolis, MN). (jafib.com)
  • Background: Transcatheter aortic valve replacement (TAVR) is the gold standard for severe valvular aortic stenosis in patients at high/prohibitive surgical risk. (elsevier.com)
  • The aim of this study is to describe procedural and early outcomes of patients with previous MV prostheses undergoing TAVR. (elsevier.com)
  • 5 mm, with 1 complicated by TAVR prosthesis embolization. (elsevier.com)
  • Conclusions: TAVR in patients with previous mitral prostheses appears to be safe and feasible, with good hemodynamic results at 30-day and at longer-term follow-up. (elsevier.com)
  • Before the advent of transcatheter aortic valve replacement (TAVR)-now a well-established alternative to surgical replacement of severely stenotic aortic valves (AVs)-patients with severe AV disease and problematic anatomic features (eg, previous sternotomy, previous chest radiation therapy, severe calcification of the ascending aorta) were difficult to treat surgically. (allenpress.com)
  • Coronary cannulation failures following transcatheter aortic valve replacement (TAVR) were found to be higher in patients receiving Evolut TAVs, according to a study published in the Journal of American College of Cardiology: Cardiovascular Interventions . (thecardiologyadvisor.com)
  • These data indicated that cannulization after a TAVR procedure was most likely to be unsuccessful after the implantation of an Evolut device. (thecardiologyadvisor.com)
  • While transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic stenosis, a new study in the American Journal of Cardiology showed that there may be a high risk of in-hospital mortality for patients who undergo surgical aortic valve replacement (SAVR) after TAVR. (ctsnet.org)
  • Advances in the diagnosis and management of congenital heart disease (CHD) have resulted in an increased number of patients living into adulthood. (hvt-journal.com)
  • In this case study, we'll focus on the advancements in the treatment of late sequelae of tetralogy of Fallot - a complex congenital heart disease. (zortrax.com)
  • 1 Other congenital abnormalities of the aortic valve, degenerative calcific aortic stenosis, aortic insufficiency secondary to connective tissue disorders, and rheumatic aortic valve disease, are also predisposing lesions for infection. (mhmedical.com)
  • Prosthesis-Patient Mismatch in Patients Undergoing Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry. (ucla.edu)
  • Valve prosthesis-patient mismatch (VP-PM): a long-term perspective. (ucla.edu)
  • Predicting the occurrence of valve prosthesis-patient mismatch: the need for more data. (ucla.edu)
  • Tanné D, Kadem L, Rieu R, Pibarot P. Hemodynamic Impact of Mitral Prosthesis-Patient Mismatch: An in Silico Study. (concordia.ca)
  • Objective: The aim of this retrospective study was to compare early postoperative outcomes after aortic valve replacement (AVR) with sutureless bioprostheses and conventional stented bioprostheses implanted through median sternotomy. (northumbria.ac.uk)
  • Quantitative assessment of PVL severity before and after BPD is mandatory to properly assess PVL, thus improving implantation results and outcomes. (sanarmed.com)
  • Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement: Results From the Transcatheter Valve Therapy Registry. (ucdenver.edu)
  • This procedure has also been used in patients with previous mitral valve (MV) prostheses, with contrasting outcomes reported. (elsevier.com)
  • Short and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial. (bmj.com)
  • Our minimally invasive transcatheter mitral valve repair therapy delivers excellent outcomes, and are particularly valuable for select patients who are not eligible for surgical valve repair. (structuralheart.abbott)
  • To determine the impact of aortic root replacement (ARR) with a stentless bioprosthetic valve on midterm outcomes compared to a stented bioprosthetic valve-graft conduit. (semthorcardiovascsurg.com)
  • A total of 1:1 nearest neighbor propensity matching was employed to assess the association of stentless valves with short-term and midterm outcomes. (semthorcardiovascsurg.com)
  • Percutaneous heart valve in the chronic in vitro testing model. (bcm.edu)
  • Kar B, Delgado RM, Civitello AB, Loyalka P, Paniagua D, Fish RD, Forrester MD, Moser D, Radovancevic B " Temporary support with Tandemheart pVAD during percutaneous aortic valve replacement in an animal model: rationale and methodology. . (bcm.edu)
  • The Carillon, Cardioband, and Mitralign all received CE marking for percutaneous mitral annuloplasty, while the Tendyne and SAPIEN 3 received a CE mark and FDA approval, respectively, for transcatheter mitral valve replacement. (cornell.edu)
  • Although percutaneous devices will appear and disappear from use, understanding the procedural considerations remains highly relevant, as these key principles will apply to the next generation of transcatheter valve interventions. (cornell.edu)
  • Because of the drawbacks associated with conventional open-heart surgery, percutaneous and minimally-invasive surgical approaches are garnering intense attention. (justia.com)
  • 5,411,522 and 6,730,118, which are incorporated herein by reference, describe collapsible transcatheter heart valves that can be percutaneously introduced in a compressed state on a catheter and expanded in the desired position by balloon inflation or by utilization of a self-expanding frame or stent. (justia.com)
  • Stent fracture, valve dysfunction, and right ventricular outflow tract reintervention after transcatheter pulmonary valve implantation: patient-related and procedural risk factors in the US Melody valve trial. (bmj.com)
  • Other interventions such as stent implantations in peripheral vessels or heart pacemaker implantations cause similar problems. (uni-rostock.de)
  • Complex Tricuspid Valve Repair in Patients With Pacer Defibrillator-Related Tricuspid Regurgitation. (uchicago.edu)
  • Hemodynamics of concomitant tricuspid valve procedures at LVAD implantation. (uchicago.edu)
  • Effect of Concomitant Tricuspid Valve Surgery With Left Ventricular Assist Device Implantation. (uchicago.edu)
  • Consequently an integrated system is developed, comprising the implant and tricuspid valve annulus. (neocor.ru)
  • However, the risks associated with surgical aortic valve replacement are increased in elderly patients and those with concomitant severe systolic heart failure or coronary artery disease, as well as in patients with comorbidities such as cerebrovascular and peripheral arterial disease, chronic kidney disease, and chronic respiratory dysfunction. (medscape.com)
  • There were ongoing discussions with FDA and many experts to develop a new classification schema for bioprosthetic valve dysfunction and failure. (houstonmethodist.org)
  • Background: Primary graft dysfunction remains the leading cause of 30-day mortality after heart transplantation. (researchgate.net)
  • Smadi O, Garcia J, Pibarot P, Gaillard E, Hassan I, Kadem L. Accuracy of Doppler-Echocardiographic Parameters for the Detection of Aortic Bileaflet Mechanical Prosthetic Valve Dysfunction. (concordia.ca)
  • The procedure resulted in angiographically and qualitatively similar forward flow across the newly implanted prosthesis and the existing apicoaortic conduit, with no hemodynamic or electrical dysfunction. (allenpress.com)
  • The presence of a systolic murmur does not indicate valve dysfunction. (syrianclinic.com)
  • Extensive, devastating prosthetic aortic valve endocarditis. (nel.edu)
  • In this report, we present a case of a 68-year-old male who developed extensive, devastating prosthetic valve endocarditis (PVE) several. (nel.edu)
  • We describe what is, to our knowledge, the first case of prosthetic valve endocarditis caused by the newly described micrococcal species, Kytococcus schroeteri . (cdc.gov)
  • Ten weeks later, the patient was admitted to the hospital because of fever of 39°C. Laboratory studies showed a leukocyte count of 15.3 x 10 9 /L with 87% neutrophils and elevated C-reactive protein (180 mg/L). Transesophageal echocardiography and computed tomography suggested an abscess next to the prosthesis and showed vegetations on the prosthetic valve, which suggested endocarditis. (cdc.gov)
  • Complex Mitral Valve Repair in a 2-Year-Old Child With Severe Infective Endocarditis. (autotissue.de)
  • Infective endocarditis is a disease in which a microorganism colonizes a focus in the heart, producing fever, heart murmur, splenomegaly, embolic manifestations, and bacteremia or fungemia. (mhmedical.com)
  • Among patients with aortic valve endocarditis, congenitally bicuspid aortic valve is the most common predisposing lesion. (mhmedical.com)
  • Patients with prosthetic heart valves have a constant risk of developing infective endocarditis. (mhmedical.com)
  • It is difficult to determine the incidence and prevalence of native aortic valve endocarditis in the general population because this disease is continuously changing. (mhmedical.com)
  • Patients with prosthetic aortic valves are reported to have an incidence of infective endocarditis of 0.2 to 1.4 episodes per 100 patient-years, which varies with the type of aortic valve. (mhmedical.com)
  • 6-12 Approximately 1.4% of patients undergoing aortic valve replacement develop prosthetic valve endocarditis during the first postoperative year. (mhmedical.com)
  • Imaging revealed severe native aortic valve insufficiency and calcification, with worsening left ventricular function. (allenpress.com)
  • This report offers some guidance for treating patients with existing apicoaortic conduits and suggests that transcatheter aortic valve replacement is safe and effective if native aortic valve insufficiency develops. (allenpress.com)
  • A potential limitation of this study was the choice to not include position of the TAV commissures in relation with the native aortic valve. (thecardiologyadvisor.com)
  • 0.016), had more frequent atrial fibrillation (P = 0.017), smaller mitral valve area (P = 0.021) and higher pulmonary artery pressure (P = 0.012) compared to patients without thromboembolism. (bvsalud.org)
  • Tanné D, Bertrand E, Kadem L, Pibarot P, Rieu R. Assessment of left heart and pulmonary circulation flow dynamics by a new pulsed mock circulatory system. (concordia.ca)
  • Mikhail A, Di Labbio G, Darwish A, Kadem L. How pulmonary valve regurgitation after tetralogy of fallot repair changes the flow dynamics in the right ventricle: An in vitro study. (concordia.ca)
  • They were challenged with a problem of a significant narrowing of pulmonary homograft (prosthesis) previously operated for tetralogy of Fallot, since the next similar surgery would be considered a high-risk. (zortrax.com)
  • Pulmonary valve replacement in adults late after repair of tetralogy of Fallot: are we operating too late? (bmj.com)
  • Part 1: aortic and pulmonary regurgitation (native valve disease). (bmj.com)
  • Late pulmonary valve replacement after repair of tetralogy of Fallot. (bmj.com)
  • One-year follow-up of the Melody transcatheter pulmonary valve multicenter post-approval study. (bmj.com)
  • These are cadaveric aortic or pulmonary valves. (syrianclinic.com)
  • Upper Ministernotomy for Pulmonary Valve Repair. (autotissue.de)
  • Journal of the American Heart Association , 08.11.2022, p. e025121. (au.dk)
  • European Heart Journal , 20.10.2022. (au.dk)
  • Tex Heart Inst J (2022) 49 (5): e227889. (allenpress.com)
  • On November 2, 2022, the American College of Cardiology (ACC) and American Heart Association (AHA) published an update to the 2010 ACC/AHA Guidelines for the Diagnosis and Management of Aortic Disease. (ctsnet.org)
  • The stroke volume index across the new bioprosthetic valve was low (13 mL/m 2 at 1 mo and 18 mL/m 2 at 1 y), suggesting that a substantial amount of blood was still exiting the ventricle through the left ventricle-to-aorta conduit. (allenpress.com)
  • 1 This apicoaortic conduit included a bioprosthetic valve to prevent regurgitation of blood into the LV. (allenpress.com)
  • Of the patients with a complete ARR, bioprosthetic valve implants were included, while mechanical valve implants were excluded. (semthorcardiovascsurg.com)
  • of these, 139 received a Perceval S sutureless valve (Group A) and 624 received a Perimount Magna Ease valve (Group B). These groups were further divided into A1 (isolated Perceval AVR), A2 (Perceval AVR with coronary artery bypass grafting [CABG]), B1 (isolated conventional stented bioprosthesis), and B2 (conventional stented bioprosthesis + CABG). (northumbria.ac.uk)
  • Coronary artery bypass surgery on a beating HEART without a CARDIOPULMONARY BYPASS (diverting the flow of blood from the heart and lungs through an oxygenator). (harvard.edu)
  • On-pump beating-heart coronary artery bypass grafting in high-risk patients: A systematic review and meta-analysis. (harvard.edu)
  • METHODS: This was a study of a pilot pathway performed at Barts Heart Centre for the admission of patients requiring elective coronary and structural procedures during the COVID-19 pandemic (April-June 2020). (bvsalud.org)
  • Heart Transplantation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (wakehealth.edu)
  • This graph shows the total number of publications written about "Heart Transplantation" by people in this website by year, and whether "Heart Transplantation" was a major or minor topic of these publications. (wakehealth.edu)
  • Below are the most recent publications written about "Heart Transplantation" by people in Profiles. (wakehealth.edu)
  • His clinical and research interests include lung and heart transplantation, ECLS/ECMO and mechanical circulatory support. (osu.edu)
  • DI-fusion Long-term durability of three mechanical valves. (ac.be)
  • What are the different kinds of mechanical valves? (syrianclinic.com)
  • Differential flow improvements after valve replacements in bicuspid aortic valve disease: a cardiovascular magnetic resonance assessment. (ox.ac.uk)
  • BACKGROUND: Abnormal aortic flow patterns in bicuspid aortic valve disease (BAV) may be partly responsible for the associated aortic dilation. (ox.ac.uk)
  • Método: Estudio descriptivo, retrospectivo, de todas las llamadas telefónicas registradas entre junio de 2020 y abril de 2021 en una consulta específica de enfermería para la atención a la insuficiencia cardiaca. (bvsalud.org)
  • Method: Descriptive, retrospective study of all telephone calls recorded between June 2020 and April 2021 in a specific nursing consultation for heart failure care. (bvsalud.org)
  • Aims: The Valve Academic Research Consortium (VARC), founded in 2010, was intended to (i) identify appropriate clinical endpoints and (ii) standardize definitions of these endpoints for transcatheter and surgical aortic valve clinical trials. (houstonmethodist.org)
  • This document provides an update of the most appropriate clinical endpoint definitions to be used in the conduct of transcatheter and surgical aortic valve clinical research. (houstonmethodist.org)
  • Conclusions: Acknowledging the dynamic and evolving nature of less-invasive aortic valve therapies, further refinements of clinical research processes are required. (houstonmethodist.org)
  • Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice: Findings From EXTEND-CoreValve. (ucdenver.edu)
  • The tests may also include those for pre-clinical in vivo evaluation and clinical evaluation of the finished heart valve substitute. (iso.org)
  • ISO 5840:2005 imposes design specifications and minimum performance specifications for heart valve substitutes where adequate scientific and/or clinical evidence exists for their justification. (iso.org)
  • Mark Ricciardi, MD, discusses clinical trials and an experienced research team, researching the most innovative treatment for interventional and structural heart issues. (northshore.org)
  • The management of conduction abnormalities after transcatheter aortic valve implantation is based on the clinical status of our patient and ECG monitoring. (imedpub.com)
  • 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (bmj.com)
  • Echocardiographic and Clinical Follow-up After Aortic Valve Neocuspidization Using Autologous Pericardium. (unibas.ch)
  • Case 1 had an artificial mitral valve implant. (who.int)
  • It excludes heart valve substitutes designed for implantation in artificial hearts or heart assist devices. (iso.org)
  • The alternative, the new method of treatment is the implantation of an artificial valve through the femoral vein. (zortrax.com)
  • 5 ],[ 12 ] Furthermore, the interaction between atrial fibrillation and other conduction abnormalities, including those requiring permanent pacemaker implantation (PPM), has not been well investigated. (jafib.com)
  • Data standards for atrial fibrillation/flutter and catheter ablation : The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). (au.dk)
  • Real-time three-dimensional transesophageal echocardiography in valve disease: comparison with surgical findings and evaluation of prosthetic valves. (uchicago.edu)
  • they are more resistant to reinfection than other prosthetic valves. (syrianclinic.com)
  • In one common surgical procedure, the diseased native valve leaflets are excised and a prosthetic valve is sutured to the surrounding tissue at the valve annulus. (justia.com)
  • Due to these risks, a substantial number of patients with defective valves are deemed inoperable because their condition is too frail to withstand the procedure. (justia.com)
  • In one technique, a prosthetic valve is configured to be implanted in a much less invasive procedure by way of catheterization. (justia.com)
  • At the conference, Thourani recalled that the idea for the device came when he described a particularly difficult surgical case to Jimenez. Thourani said that a principal motivation for the device came for the need to prevent bleeding after the valve repair procedure is completed. (emoryhealthsciblog.com)
  • Transcatheter aortic valve implantation is a procedure that allows the aortic valve replacement via minimally invasive technique. (imedpub.com)
  • Fusion imaging of pre- and post-procedural computed tomography angiography in transcatheter aortic valve implantation patients: evaluation of prosthesis position and its influence on new conduction disturbances. (uniklinik-freiburg.de)
  • A man with severe rheumatic trivalvular disease was treated with surgical implantation of mechanical aortic and mitral prostheses at the age of 30 years and tricuspid bioprosthesis at the age of 50 years. (ajconline.org)
  • Prior reports have documented an increased incidence of conduction abnormalities and other arrhythmias after aortic valve replacement, whether via a surgical or catheter-based approach. (jafib.com)
  • Unexpected suicide left ventricle post-surgical aortic valve replacement requiring veno-arterial extracorporeal membrane oxygenation support despite gold-standard therapy: a case report. (stacksdiscovery.com)
  • Mirvakili N, Di Labbio G, Saleh W, Kadem L. Flow characteristics in a model of a left ventricle in the presence of a dysfunctional mitral mechanical heart valve. (concordia.ca)
  • Mouret F, Kadem L, Bertrand E, Dumesnil JG, Pibarot P, Rieu R. Mitral Prosthesis Opening and Flow Dynamics in a Model of Left Ventricle: an in vitro Study on a Monoleaflet Mechanical Valve. (concordia.ca)
  • Di Labbio G, Vétel J, Kadem L. Material transport in the left ventricle with aortic valve regurgitation. (concordia.ca)
  • Di Labbio G, Ben Assa E, Kadem L. Experimental Investigation of the Effect of Heart Rate on Flow in the Left Ventricle in Health and Disease-Aortic Valve Regurgitation. (concordia.ca)
  • A condition in which the mitral valve does not close completely during the contraction of the left ventricle, causing blood to leak backward into the left atrium. (structuralheart.abbott)
  • A narrowing of the aortic valve, which reduces or blocks blood flow from the left ventricle to the aorta. (structuralheart.abbott)
  • 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. (bmj.com)
  • Mark Ricciardi, MD, gives an overview of NorthShore contributions to evolution of interventional cardiology and structural heart management. (northshore.org)